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ABSTRACT 
Sequential testing, using a wide spectrum of 
clotting tests, most of which were designed for this 
study, was performed on dilute whole blood samples 
obtained from a series of 25 patients who underwent a 
variety of major elective surgical procedures. Testing 
commenced prior to surgery and thereafter at intervals 
during the first 7 to 10 days postoperatively. Clotting 
test results were compared to the pre-operative mean 
values so that each patient acted as his own control. 
Very shortly after surgery, increased in vitro 
coagulability was demonstrated in almost all patients by 
the use of the phase 1, phase 2, heparin resistance, 
autocoagulography and autocoagulography control tests. 
A peak increase in coagulability was found between days 
3 to 5, with a smaller peak occurring on or around the 
eight day postoperative. The results of the phase 3 
test showed marked dispersion in some patients, while 
others gave results consistent with increased coagula-
bility. 
Plasma fibrinogen concentration and the platelet 
count both increased early in the postoperative period and 
thereafter increased progressively. The results of the 
two universally used tests of haemostasis, namely the 
prothrombin time and the kaolin-cephalin clotting time 
lll 
were comparatively poor indicators of the postoperative 
increase in coagulability demonstrated by the phase 1, 
phase 2, heparin resistance, autocoagulography and auto-
• 
coagulography control tests, although the results of the 
phase 3 test were somewhat similar to those found using 
the prothrombin time. 
This study has demonstrated that in the majority 
of patients a postoperative increase in the concentration 
of serum fibrin(ogen) degradation products is found at 
some time during the first 7 days following surgery. 
Clot retraction, studied with an original 
technique, was found to increase in approximately 50% 
of patients during the first 3 postoperative days. 
During the first 7 days following major elective 
surgery, the rise in the fibrinogen concentration and 
in the platelet count, and the inc+ease in the concentration 
of serum fibriniogen) degradation products indicates that, 
in attempting to detect haemostatic failure in the post-
operative patient, evaluation of haemostatic tests should 
not be made using the so-called "normal values". The 
author suggests that postoperative evaluation of haemostasis 
be compared to values obtained prior to surgery. 
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INTRODUCTION 
REVIEW OF THE RELEVANT LITERATURE 
The Issue of Hypercoagulability. 
Haemorrhagic disorders are often associated 
with a deficiency of one or more of the blood clotting 
factors which have been officially recognized by the 
International Committie on Nomenclature, and dignified 
by the assignment of a roman numeral. Usually such 
disorders are demonstrated by the finding of an increase 
in the time required for whole blood or plasma to clot 
in tests which are sensitive to the factor or factors 
which are reduced in concentration. Such disorders 
are examples o£ the hypocoagulahle state. 
In contrast, the blood of certain individuals 
is characterized by an increase in either, or both of 
the activity or concentration of one or more of the 
blood clotting factors. This increase may sometimes 
be demonstrated by noting a shortening of the time 
required for whole blood or plasma to clot in tests which 
are sensitive to the factor or factors which are increased 
in concentration or activity. Such a state has been 
referred to as a hyperc·oagulable state. Although the 
demonstration of in Vitro hypercoagulability may be 
acheived, hypercoagulability in the patient is still 
2. 
hypothetical. 
To define hypercoagulability in this way how-
ever, may represent an oversimplification. The term 
has acquired a diversity of connotations and has become 
popular during a period of active experimental investi-
gations of i .n vivo coagulation, as well as during wide-
spread studies of clinical conditions associated with 
thrombosis or disseminated intravascular coagulation. 
Specifically, the term has been applied to; 1) changes 
in the concentration of clotting and/or fibrinolytic 
factors such that in vi~ro clotting tests are accelerated 
(Spittell et al 1961, Hume & Chan 1967, Skjodt 1967), 
2) a stage of intravascular coagulation during which 
clotting factors are activated (Botti & Ratnoff 1964, 
Niemetz & Nossel 1967), and 3) the experimental initiation 
of intravascular clotting by the injection of tissue 
thromboplastin, (Penick et al 1958, Rapaport et al 1963, 
Izak & Falewsky 1966, Nossel 1967), thrombin, (Warner et 
al 1939, Rapaport et al 1963, Kowalski ·et ·al 1965, 
Margaretten et al 1967), and activated clotting factors 
(Arakawa & Spaet 1964, Deykin 1966). 
On the other hand, many clinicians would prefer 
to define hypercoagulability as a clinical state in which 
we know intravascular thrombi are prone to develop and 
would welcome clues to its presence. 
The term hypercoagulability is highly subjective, 
having a somewhat nebulous character and has remained 
3. 
difficult to define by laboratory investigations for the 
following reasons. Hypercoagulability does not mean the 
same state when used by different people. There is a 
wide variation in the normal levels of blood clotting 
factors in persons of the same age and sex (though one 
person's level may remain constant). So that a patient 
with a usual level at the upper end of the normal range 
of any clotting test might be said to be in a hypercoagu-
lable state if his test result changed to the mid normal 
range. Whereas a patient with a usual level in the mid 
normal range would have to change to the low normal range 
before one could define the state of his blood as hyper-
coagulable. Thus unless one knows a patient's usual 
level, it is difficult to comment on the result of a test 
in the postoperative period or during a serious illness. 
In spite of the somewhat nebulous nature of the 
hypercoagulable state, it is generally held by clinicians 
that such a state does exist in certain types of patients. 
The lineage of the hypercoagulable state does appear to 
have some measure of respectability. Wiseman (1676), 
described the properties of a thrombus and stated that 
intravascular occlusion was related, in part, to systemic 
alterations in the circulating blood. Virchow (1856), 
some 200 years later, made almost passing reference to 
hypercoagulability and ennunciated his famous triad of 
factors influencing the pathogenesis of venous occlusion. 
In the same paper he introduced the term "thrombosis", 
probably Ln ~n atte.m~t to empha~ize ~s opposition to 
the concepts prevailing in his time, regarding the 
mechanisms of spontaneous intravascular occlusion. 
He refuted Hunter's theory of "inflammation of the 
4. 
inner layer of the vein" as being the fundamental patho-
genetic process in thrombosis. He denied Bichat's 
concept of "excessive tendency of the vein for inflamma-
tion. Virchow was the first to realize that an altera-
tion in the balance between procoagulant and anticoagulant 
forces within the circulating bloodstream could play a 
role in the establishment of intravascular thrombi. 
Virchow's original hypothesis, that it was mainly contact 
with air or oxygen that induced blood to clot was modi-
fied since he was unable to explain all cases of thrombosis 
with this blood-gas contact hypothesis. His modification, 
the oft cited "Triad of Virchow", remains as valid today 
as at the time of its ennunciation, and states that the 
formation of intravascular fibrinous occlusions results 
from the interplay of alterations in a) blood flow, 
b) the vessel and c) the biochemical factors in the blood. 
The Hypercoagulable State in Medical Patients 
Since the end of World War II, blood clotting 
factors have been discovered in rapid successsion, 
largely by the recognition of congenital deficiency states 
inindividual patients with haemorrhagic diatheses. 
5. 
The ~dentificat~on and partial characterization of each 
new clotting factor has often raised hopes that the fac-
tor may play a key role in the pathogenesis of thrombo-
embolic diseases, most of which appear to be characterized 
by some laboratory manifestation of hypercoagulability. 
It has been assumed that the hypercoagulable state pre-
disposes to thromboembolism, although direct evidence 
for a cause and effect relationship is still lacking. 
Nevertheless, certain clinical conditions are known to 
be associated with an increased incidence of thrombo-
embolism including; malignancy (Sproul 1938, Byrd et al 
1947, Amundsen et al 1963, Levin & Conley 1964, Thornes 
et al 1967 and Brugarolas et al 1973), arteriosclerosis 
obliterans (Pascuzzi et al 1961), coronary artery disease 
(Wright & Marple 1954, McDonald & Edgill 1957 a, b, 
Mersky et al 1960, Cooperberg & Teitelbaum 1961, Chakra-
bati et al 1968), thrombophlebitis (Durham 1955, Egeberg 
1965, Hume 1966), pregnancy and the peurperium (Dieckman 
& Wagner 1934, Pechet & Alexander 1961, Strauss & 
Diamond 1963, Todd et al 1965, Nessel et al 1966, Paller 
& Thomson 1966, Bonnar et al 1970), ulcerative colitis 
(Lee et al 1968), homocystinuria (McDonald & Bray 1968), 
polycythaemia (Dawson & Ogston 1970), diabetes mellitus 
(Moolten et al 1963, Egeberg 1963, Fearnley et al 1963, 
Hellern et al 1964, Bridges et al 1965, Shaw et al 1967, 
Chmielewski & Farbiszewski 1970), trauma (Innes & Sevitt 
6. 
1964, Sevitt 1969), and in women who use oral contra-
eptives (Rutherford et al 1964, Houghie et al 1965, 
Kaulla & Kaulla 1970, Fagerhof & Abilgaard 1970, and 
Howie et al 1970) • 
The Hypercoagulable State in Po·sto·pera·tive 
Patients 
Following surgical operations, there are 
changes in many of the properties of the blood which are 
important in haemostasis. Many studies have been 
performed to determine the physiological response to 
surgical trauma, and a wide variety of haemostatic para-
meters have been studied. Perhaps the most consistent 
change found in the postoperative period is the rapid rise 
in the level of circulating fibrinogen (Warren et al 1950, 
Atkins & Hawkins 1969, Ygge 1970 a, b, Hammer· et al 1973). 
Another well documented change involves the circulating 
numbers of platelets. Dawbarn et al (1928}, Potts & 
Pearl (1941), Ham & Slack (1967) and Fogli.ano et al (1973) 
all reported increases in the numbers of circulating 
platelets in the postoperative period. The increase in 
the platelet count is commonly subsequent to an early 
postoperative decrease. Increases in the adhesiveness 
of platelets in the postoperative patient have been docu-
mented by Wright (1942), Emmons & Mitchell (1963), Hirsh 
~ al (1966}, Bygdeman ·et ·al (1968), Negus ·et ·al (1969}, 
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and by O'Brien et al (1974}. The property of platelet 
aggregation in response to the addition of certain 
stimuli, such as collagen, adrenalin and adenosine di-
phosphate, the subject of much intensive study during 
the past decade, has also been shown to alter following 
surgical trauma. Enticknap et al (1970}, demonstrated 
an increase, in the early postoperative period, in the 
numbers of platelets that aggregate in response to the 
addition of adenosine diphosphate. :c O'Brien et al (1971}, 
demonstrated a transient period occurring in the late 
operative and early postoperative period, in which plate-
lets became refractory to the addition of such stimuli as 
collagen and adenosine diphosphate. Additional changes 
which have been documented as part of the haemostatic 
alteration in response to surgical trauma include; 
increased concentrations of factors VIII, IX and X (Ege-
berg 1962, Davidson & Tomlin 1963, Nilchen & Nilsson 1967, 
and Ygge 1970 a,b}, increased consumpti.on of prothrombin 
(Williams & Warren 1957), and a decrease in plasminogen 
and spontaneous fibrinolytic activity (Ygge 1970 a, b). 
Another approach to the study of in vitro 
hypercoagulability during the postoperative period has 
been to examine changes in the activity of clotting factors 
in whole blood or plasma samples. Shortening of the clotting 
times of whole blood and plasma has been reported by 
Peller (1956), Gardikas et al (1959), Feruglio et al (1960), 
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Eastham & Johnson (1963) and by Eastham & Morgan (1964). 
shortening of the clotting times of whole blood and plasma 
in the presence of very small amounts of heparin (heparin 
resistance test) have also been documented by DeTakats 
(1943), Waugh & Ruddick (1944), DeTakats & Marshall (1952), 
Gardikas et al (1959), Holger-Madsen & Schiolar (1959), 
Gormsen & Haxholdt (1960), Feruglio et al (1960), Godal 
& Fichera (1961), Gormsen & Haxholdt (1961), Eastham & 
Johnson (1963). Postoperative shortening of the clotting 
times of whole blood held in siliconized test tubes has 
been documented by McClerry et al (1952) • The prothrom-
bin time of whole blood or dilute plasma may also shorten 
during the postoperative period as was demonstrated by 
Brambell & Loker (1943), Sandrock & Maloney (1948) and 
by Warren et al (1950). 
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Aims of the Study. 
The greater majority of studies directed towards 
determining the haemostatic changes resulting from surgi-
cal operations have been characterized by one or more of 
the following; a) study of the concentration of speci- · 
fie clotting factors in plasma samples using specific 
factor assays, b) study of the activity of groups of 
clotting factors by the use of non-specific tests per-
formed on plasma samples. Some of the latter tests, 
e.g. the prothrombin time and partial thromboplastin 
time, are universally used and have proven sensitivity 
to clotting factor deficiencies, but not to increases 
in clotting factors and/or activity, and c) comparison 
of results of clotting tests performed on patient samples 
with normal values obtained from the testing of samples 
drawn from "healthy" persons. 
Studies having these characteristics may be open 
to criticism on the following grounds. Cell poor plasma 
is an artificial sample and is not representative of the 
circulating blood. The use of well established tests, 
such as those cited above, without modification, to follow 
the development of a hypercoagulable state is questionable 
since it is likely that the kinetics of clotting in factor 
deficient plasma samples is quite different from those in 
plasma samples containing an excess of one or more factors. 
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since the normal range of clotting factors is so wide, 
very significant alterations in the level of one or 
more clotting factors, following some appropriate stimu-
lus, might be described as being within "normal limits" 
in spite of changes which may readily exceed 100% of 
the pre-stimulus value. 
With these thoughts in mind, this study was 
performed in order to follow the haemostatic changes 
following surgery using; a) whole blood samples, b) 
test systems utilizing dilute whole blood, in an effort 
to increase the sensitivity of the tests to increases 
in clotting factors or activity, and c) the patient's 
pre-operative haernostatic test results as the baseline 
to which all postoperative results would be compared, 
that it, the patient acts as hi.s own control. Finally, 
the entire spectrum of clotting tests would be used with 
each patient in a sequential manner. 
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MATERIALS AND METHODS 
A) MATERTALS 
De-ionized water. 
Water used for the preparation of all solutions 
and reagents was freshly de-ionized by passage through a 
Barnstead de-mineralizer charged with a mixed bed resin. 
The resistance of such water was always in excess of l 
megohm. 
Tris (Tris Hydroxymethyl Aminomethane) Buffer 
(Fisher Scientific Co., Toronto, Ontario). 
Tris buffer was made up according to Gomori 
(1946). A stock solution of O.lM tris was prepared. 
To 500ml. of this stock solution, 414ml. of O.lM HCl 
and 6.58 grams of dried sodium chloride was added. 
Following complete dissolution of the added chemi.cals, 
the volume was made up to lOOOml. with de-ionized water. 
The pH of the buffer solution was checked with a pH meter 
and adjusted to pH 7.4 if necessary. 
Heparin Solution 
Heparin, 1,000 international units per ml. 
(M.T.C.Pharmaceuticals, Hamilton, Ontario) was diluted 
with tris buffer to give a solution of 1,000 international 
units per lOOml. 
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Calcium Chloride Solution 
A 0.025M solution was prepared by adding 2.75 
grams of anhydrous calcium chloride to de-ionized 
water. Following complete dissolution of the chloride, 
the volume was made up to l,OOOml. with de-ionized water. 
Thrombo-Wellcotest Kit 
Used in the determination of serum fibrin(ogen) 
degradation products. (Warner Chilcott Laboratories). 
Ca5tor 0~1 (U.S.P.). 
1% w/v Celi te in Tris BU:ff·e:r. 
For the preparation of this reagent, Celite 
512 A.W. (John's Manville Product, Hartman Leddon Co., 
Philadelphia), was used. 
Ti.ssue Thromboplastin · (Sirnplas·tin) . 
(Warner Chilcott Laboratories, Toronto, Ontario) 
This preparation of rabbit brain thromboplastin 
contains an added optimum concentration of calcium 
chloride and was used only for the phase 3 test. 
Brain Thromboplastin 
(Ortho Pharmaceuticals, Don Mills, Ontario). 
Used in the determination of the one stage 
prothrombin time. 
Hypertonic Sodi urn Chlo·r ·ide So lt1tio·n. 
A 1.8% w/v solution was prepared using anhy-
drous sodium chloride. 
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Sodium ci·tr·at·e · Anti·co·a ·g·ul·ant 
A 3.8% w/v solution was prepared and sterilized 
in small volumes. 
Prothrombin Test Unit Re·action Chambers 
(Fisher Scientific Co., Toronto, Ontario). 
Micro-projector, Tri-Simplex, Bausch & ·Lo·mb 
(Canadian Laboratory Supplies, Toronto, Ontario} 
The micro-projector was modified in the following 
manner. A clear plastic box 18 inches long, by 9 inches 
wide and 2 inches high was fixed to the stage of the micro-
projector~ 
0 
By means of a pump, water maintained at 37 C 
was delivered to the box and returned to the pump. The 
arrangement of the delivery and return water lines, per-
mitted a constant depth of water of 1~ inches. 
Automatic Pip~ttes 
For dispensing O.lml. and 0.2ml. volumes, a 
Fibrometer automatic pipette (Canadian Laboratory Supplies, 
Toronto, Ontario) with disposable tips was used. For the 
dispensing of O.Sml. and l.Oml. volumes, Oxford automatic 
pipettes with disposable tips were used. (Canadian Labora-
tory Supplies, Toronto, Ontario). For the dispensing of 
the heparin solution, a 100 micro-litre, Hamilton gas-tight 
syringe, fitted with a Chaney adaptor and delivery stops 
was used (Canadian Laboratory Supplies, Toronto, Ontario). 
Polystyrene Tubes with Polyethyl·en:e Caps. 
(Luckham Ltd., Burgess Hill, Sussex, England). 
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B) ME'THODS 
Collection of Venous Blood Samples. 
Venous blood samples were obtained from a promi-
nent ante-cubital vein using a two-plastic syringe tech-
nique, with minimal tourniquet induced stasis. Follo-
wing the light application of a tourniquet and cleansing 
of the puncture site, the first plastic syringe, bearing 
a 19 gauge, l inch needle, was used to collect Sml. of 
venous blood, 2ml. of which were immediately added to 
a vial containing thrombin/trayslol (supplied with the 
Thrombo-Wellcotest Kit) , the vi.al contents were then 
thoroughly mixed. The remaining 3mls. were rapidly 
discharged into vacutainer tubes containing 1% ethylene-
diamine tetra-acetic acid and thorough mixing accomplished. 
The second syringe, containing lml. of 3.8% sodium citrate 
was then attached to the needle, left in situ, and 9mls. 
of venous blood were slowly collected. Following sample 
collection, the needle was removed and the syringe piston 
was withdrawn slightly to permit mixing of the syringe 
contents, which was accomplished by slowly inverting the 
syringe 10 times. The anticoagulated blood was then 
slowly dispensed into a polystyrene tube and closed with 
a polyethylene cap. 
Blood samples were then taken to the laboratory 
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for immediate processing and testl..ng. The testing of all 
blood samples during the study con:unenced within 30 minutes 
of phlebotomy. 
Preparati·on of Blood for Te·s ·tin:g 
a) Preparation of non-contact activated whole 
blood. 
Into a polystyrene tube containLng 2.5ml. of 
tris buffer, 2.5ml. of venous whole blood was added. 
The tube was closed with a polyethylene cap and the con-
tents mixed by inverting the tube 10 times. The tube 
was then placed in the 37°C water bath. 
b) Preparati.on of contact activated whole 
blood. 
Into a polystyrene tube c~ntaining 2.5ml. of 
1% celite in tris buffer prewarmed to 37°c was added 
2.5ml. of venous whole blood. Fol.lowi.ng capping, the 
tube was placed on a rotator operating at 15 revolutions 
per minute. During each cycle of the rotator, the tube 
was inunersed in the water bath, ma.tntained at 37°C, for 
180 degrees of each cycle. Rotat~on {contact activation} 
was allowed to proceed for exactly 5 minutes. Follo-
wing the termination of contact activation, the blood was 
tested immedL~tely. 
c} ~reparation of platelet poor citrated 
plasma. 
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2.5mls of citrated venous whole blood was trans-
ferred to another polystyrene tube and centrifuged at 
2,000g for 15 minutes. The supernatant platelet poor 
plasma was removed with a plastic pipette and stored in 
a polystyrene tube in ice water until testing commenced. 
Test Methods 
Phase 1 Test. 
0.2ml of the non-contact activated dilute 
whole blood was added to a polystyrene tube containing 
0.6ml. of tris buffer and 0.2ml. of 0.025M calcium 
chloride solution, all prewarmed to 37°c. A stopwatch 
was started simultaneously and the tube was gently tilted 
at one second intervals by means of a special holding 
plate. During tilting, the tube was examined by means 
of a x5 large hand lens mounted on a laboratory stand. 
The stopwatch was stopped when a firm fibrin clot formed. 
The time taken for the formation of the fibrin clot was 
recorded. 
Phase 2 Test. 
o.2ml. of contact activated dilute whole blood was 
added to a polystyrene tube containing 0.6ml. tris 
buffer and 0.2ml. Of 0.025M calcium chloride solution 
prewarmed to 37°C. A stopwatch was started simul-
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taenously and the tube was treated as already described 
for the phase 1 test. 
Phase 3 Test 
0.2ml. of contact activated dilute whole blood 
was added to a polystyrene tube containing 0.4ml. of 
tris buffer and 0.4ml. of tissue thromboplastin (Simplas-
tin), containing calcium chloride. Reagents in the 
tube were prewarmed to 37°C. A stopwatch was started 
simultaneously and the tube was then treated as already 
described for the phase 1 test. 
Heparin Resistance Test 
(Modified from Marbet & Winterstein 1950) . 
l.Oml. of contact activated dilute whole blood 
was added to a polystyrene tube containing l.Oml. of 
0.025 M calcium chloride solution and O.Olml. of heparin 
solution, both prewarmed to 37°C. A stopwatch was 
started simulataneously and the tube was treated in the 
same manner as already described for the phase 1 test. 
Autocoagulography Test 
O.lml. of contact activated dilute whole blood 
was added to a polystyrene tube containing 0.2ml. of de-
ionized water prewarmed to 37°C. The tube contents 
were quickly mixed and allowed to incubate at 37oc 
for 60 seconds. 0.2ml. of hypertonic (1.8%) sodium 
chloride solution was then added to restore isotonicity 
to the haemolysate, followed immediately by 0.5ml. of 
18. 
contact activated dilute whole blood. The tube contents 
were then mixed by tilting the tube twice and 0.5ml. of 
o.025M calcium chloride solution was added. A stop-
watch was started simultaneously and the tube was treated 
as already described for the phase 1 test. 
Autocoagulography Control Test. 
O.lml. of contact activated dilute whole blood 
was added to a polystyrene tube containing 0.4ml. of 
isotonic saline solution prewarmed to 37°C. Following 
a 60 second period of incubation, 0.5ml. of contact acti-
vated dilute whole blood was added followed immediately 
by O.Sml. of 0.025M calcium chloride solution. A stop-
watch was started simultaneously and the tube was treated 
as already described for the phase l test. 
Figures 1, 2, 3, 4, 5, and 6 found on pages 19 
to 24 respectively, illustrate the principles, reagents 
used and the clotting activity thought to be measured by 
each of the phase l, phase 2, phase 3, heparin resistance, 
autocoagulography and autocoagulography control tests. 
Gravimetric Estimation of Fibrinogen as Fibrin. 
Method based on that of Ingram {1952) . 
2.0ml. of citrated platelet poor plasma was 
recalcified by the addition of l.Oml. of 0.025M calcium 
PHASE I 
Principle. Dilute non-contact activated whole 
blood is added to a relatively large 
volume of tris buffer containing calcium ions. 
The time required for the formation of a fibrin 
clot is recorded. 
Clotting activity thought to be measured by the 
Te·st. 
Clotting activity resulting from the activation 
of all factors that participate in the intrinsic 
mechanism of blood coagulationr i.e. Factors XII, 
XI, IX, VIII, X, V, II, I, and platelets. 
Volume 
added 
0.2ml. 
I 
~ 
0.2ml. 
0 . 6ml.~ 
' 
I 
0 
_-
Reagent added 
1:2 non-contact 
activated whole blood 
0.025M calcium 
chloride. 
Tris Buffer 
Fig.l. Illustrating the principle, reagents and the 
clotting activity thought to be measured by 
the phase l test. 
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PHASE 2. 
Principle. Dilute contact activated whole 
blood is added to a relatively large 
volume of tris buffer containing calcium ions. 
The time required for the formation of a fibrin 
clot is recorded. 
Clotting Activity thought to be measured by the 
Test 
Clotting activity resulting from the activation 
of Factors IX, VIII, X, V, II, I and platelets 
in the presence of pre-activated Factors XII and 
XI. 
I 
Volume Reagent added 
Added 0 
Fig.2. 
0.2ml. 
0. 2m~ ~ . _.,/" 
·~..,......__....~ 
0. 6ml • 
l:~ contact 
activated whole 
blood. 
0.025M calcium 
chloride solution 
tris buffer 
Illustrating the principle, reagents and the 
clotting activity thought to be measured by 
the phase 2 test. 
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Phase 3. 
Principle. Dilute contact activated whole blood 
is added to tris buffer containing 
tissue thromboplastin and calcium ions. The time 
required for the formation of a fibrin clot is 
recorded. 
Cldtting activity thought to be measured by the 
Te·st 
Clotting activity resulting from the activation 
of all factors that participate in the extrinsic 
mechanism of blood coagulation, i.e. Factors X, 
VII, V, II and I. 
Volume 
Added 
0.2ml. 
I 
0 
I 
Reagent Added 
1:2 contact 
activated whole 
blood. 
0.4ml 
----~ 
tissue 
thromboplastin with 
calcium. 
0. 4ml.--o!!ll!l-. E tris buffer. 
Fig.3. Illustrating the principle, reagents and the 
clotting activity thought to be measured by 
the phase 3 test. 
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Heparin Resistance Test. 
Principle Dilute contact activated whole blood 
is added to calcium chloride contain-
ing a small concentration of heparin. The time 
required for the formation of a fibrin clot is 
recorded. 
Clotting activity thought to be measured by the 
test 
Clotting activity resulting from the activation 
of Factors IX, VIII, X, V, II, I and platelets 
in the presence of pre-activated Factors XII and 
XI and in the presence of a small amount of hep~ 
arin. 
Volume 
Added 
l.Oml 
O.Olm~ 
~ 
l.Oml. • 
I 
' 
0 
Reagent added. 
1:2 contact 
activated whole blood. 
Qo025 M calcium 
chloride solution. 
Fig.4. Illustrating the principle, reagents and the 
clotting activity thought to be measured by 
the heparin resistance test. 
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Autocoagulography Test. 
Principle. dilute contact activated whole blood 
is added to a small volume of auto-
logous haemolysate. The mixture is recalcified 
and the time required for the formation of a fibrin 
clot is recorded. 
Clotting activity thought to be measured by the 
test. 
Clotting activity resulting from the activation 
of Factors IX, VIII, X, V, II, I and platelets 
in the presence of autologous haemolysate and 
pre-activated factors ~II and XI. 
The difference between the autocoagulography 
control test and the autocoagulography test 
will reflect the coagulant activity of the red 
cells. 
Volume 
Added 
O.Sml. 
0.5~ 
0.2~ 
0.2m~ 
~ 
0 • lml -llllil!!ll.._. 
I 
' 
0 
. E 
Reagent added 
0.025M calcium 
chloride solution 
water 
1:2 contact activated 
whole blood. 
Fig.S. Illustrating the principle, reagents and the 
clotting activity thought to be measured by 
the autocoagulography test. 
23 
Autocoagulography Control Test. 
Principle. Dilute contact activated whole blood 
is added to an equal volume of the 
same blood diluted with isotonic saline solution. 
The mixture is recalcified and the time required 
for the formation of a fibrin clot is recorded. 
Clotting activity thought to be measured by the 
test. 
Clotting activity resulting from the activation 
of Factors IX, VIII, X, V, II, I and platelets 
in the presence of pre~activated Factors XII and 
XI. 
I 
Volume 
Added 
O.Sml 
O.Sm~ 
~ 
0.4ml 
~ 
0 • lml • -----!!15-. 
0 
I 
Reagent Added 
0.025M calcium chloride 
solution. 
1:2 contact activated 
whole blood. 
saline 
1:2 contact activated 
whole blood. 
Fig.6. Illustrating the principle, reagents and the 
clotting activity thought to be measured by 
the autocoagulography control test. 
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chloride solution. The tube was corked and inverted a 
number of times to effect thorough mixing. The tube 
was then placed in a water bath maintained at 37°C and 
left to incubate for 30 minutes. Following incubation, 
the clot was carefully removed and the serum expressed 
from the clot by repeatedly pressing the clot between 
circles of filter paper. The fibrin clot was then 
washed in large volumes of de-ionized water for 5 minutes, 
followed by rinsing in acetone for the same time period. 
The fibrin clot was then allowed to dry in a 37°C incubator 
for 24 hours, following which the clot was weighed on an 
analytical balance. The concentration of fibrinogen 
(as fibrin) was calculated by the use of the following 
formula: 
we·ight of f.;thrin: (mg) 
2 
x 100 = Fibrinogen mg/lOOml. plasma. 
Platelet Counts. 
Platelet counts were performed using the Thrombo-
counter. (Coulter Electronics, Miami, Florida). 
Kaolin-cephalin Clotting Time. 
The method was performed in accordance with the 
manufacturer's instructions. The kaolin-cephalin re-
agent used was obtained from Diagnostic Reagents, Thame, 
Oxon, England. Each vial of lyophilized kaolin-cephalin 
reagent was reconstituted with lOml. of freshly de-ionized 
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water and was thoroughly mixed just prior to use. 
o.2ml. of the kaolin-cephalin reagent was pipetted into 
a 10 x 75mm. glass test tube and was incubated in a water 
bath maintained at 37°C. Following incubation for 3 
minutes, O.lml. of test plasma was added and the tube was 
tilted 5 times and returned to the water bath: 60 seconds 
after the addition of the plasma, the tube was re-tilted 
5 times and again returned to the water bath. At 
exactly 2 minutes after the addition of the plasma, O.lml. 
of 0.025M calcium chloride solution was added and a stop-
watch started simultaneously. The tube was tilted once 
a second and the time required for the formation of the 
fibrin endpoint was recorded. 
One Stage Prothrombin Time 
The method was performed in accordance with the 
instructions issued by the manufacturer of the brain 
thromboplastin (Ortho Pharmaceuticals, Don Mills, Ontario). 
The lyophilized brain extract/calcium chloride reagent 
was reconstituted with 12ml. of freshly de-ionised water. 
0.2ml. of the reconstituted reagent was pipetted into a 
10 x 75mm. glass test tube and incubated for 3 minutes 
at 37°C. O.lml. of the test plasma was then pipetted 
into the tube and a stopwatch started simultaenously. 
The time required for the formation of a fibrin clot was 
recorded. 
Clot Retraction. 
l.Oml. of non-contact activated dilute whole 
blood was dispensed into a polystyrene tube containing 
o.Sml. of 0.025M calcium chloride solution pre-warmed 
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to 37oc. By means of a fibrometer pipette, fitted with 
a disposable plastic tip bearing a 21 gauge, 1 inch 
needle, O.lml. of the well mixed blood-calcium mixture 
was carefully dispensed into the bottom of a prothrombin 
test unit reaction chamber filled with castor oil warmed 
to 3 7°C. (See Figure 7, page 2 8 l . The reaction chamber 
was then placed into the plastic box containing water 
circulating constantly and being maintained at 37°C which 
was mounted on the stage of the micro-projector. The 
remaining blood in the polystyrene test tube, still held 
in the water bath, was examined until clotting resulted. 
At this time the micro-projector was switched on, focussed, 
and the projected image of the clot in the reaction 
chamber was carefully drawn on paper. This outline re-
presents the size of the clot at time zero (the time of 
clotting) . The image of the clot, maintained at 37oc 
throughout the period of observation, was redrawn at 10, 
20, 30 and 60 minutes. (See Figure 8, page 2~), Only 
the image of the clot was drawn, no attempt being made to 
outline the image of extruding serum. After the period 
of observation, the clot outline were carefully cut out 
and weighed on an analytical balance. The percent 
Fig 7. 
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Showing the clear plastic reaction 
chamber, filled with castor oil and 
containing a clot which is actively 
retracting as evidenced by the ex-
trusion of serum. The width of the 
chamber as seen from ~he top is 2 rnm. 
Fig. 8. Showing the drawn outlines of the pro-
jected image of a retracting clot at 
time zero · and at 10 minute intervals 
following clotting for the first 10 
minutes and again at 60. The times 
in the figure are superimposed on the 
clot itself. 
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retraction occurri._ng at any time interval w·as calculated 
by the use of the following formula: 
Wt.C.O.T. 0 ~ Wt.C.O.T.in 
Wt.C.O.T. 0 
x 100 = % Retraction at Tin 
Where C.O.T. 0 = weight of clot outline at time zero and 
c.o.T.in = weight of clot outline at any particular time 
interval. 
The percent retraction values were then plotted against 
time (See Figure 9, page 30 ) , and the median retractive 
index found. The median retractive index (M.R.I.) re-
presents the time at which 50% retraction occurs. A 
second indice, the maximum retractive activity time 
(M.R.A.T.} was also recorded. This indice was found by 
noting the ti.me at which peak retractive activity resulted 
based on the % retraction values obtained for each 10 
minute interval. Thus, if 20% retraction occurred at 
10 minutes and 35% retraction was found at 20 minutes, 
50% at 30 minutes and 56% at 60 minutes, then 20% re-
traction occurred during the first 10. minutes, 15% 
during the second 10 minutes, 15% during the third 10 
minutes and 6% during the last 30 minutes. These values 
were also graphically displayed (See Graph line 2, Figure 
9, page 30 } • In Figure 9, the median retractive index 
70 
6 
z 
0 50 
I-
~ 
0::: 
I-
w 
0::: 
0 
o-
10 
0 
Fig.9. 
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!/M.R.I. 
10 20 30 60 
TIME (M ins) 
Showing the manner of plotting progressive 
clot retraction over the 60 minutes period 
of observation (Graph line 1) • Graph 
line 2 shows a plot of the % retraction 
that occurs in each 10 minute period up 
to 30 minutes. The last point on this 
graph line shows the % retraction that 
occurred during the last 30 minutes of the 
period of observation. 
is 35 minutes and the max~um retractive activity time 
is 20 minutes. 
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Assay of Serum Fibrin(ogen) Degradation Products 
For this assay the Thrombo-Wellcotest kit 
supplied by Warner Chilcott Laboratories, Toronto, Ontario 
was used. 
Following incubation for 2 hours at 37°c, the 
blood collected into the vial containing thrombin/trayslol 
was centrifuged at 2,000g for 10 minutes to obtain cell 
free serum. Using the glycine buffer as a diluent, serum 
dilutions of 1:5, 1:10, 1:20, and 1:40 were routinely 
prepared. Occasionally additional dilutions were pre-
pared. The serum dilutions were tested in the follo-
wing way. Using droppers supplied with the kit, one 
drop of each serum dilution was delivered into separate 
wells on a glass slide. To each drop of serum dilution, 
1 drop of sensitized latex particles was added. Using 
wooden applicator sticks, the contents of each well were 
well mixed. At exactly 2 minutes after mixing, the 
reaction patterns were evaluated against a dark back-
ground. If an unagglutinated latex pattern was ob-
served the test was recorded as being negative. If, 
however, the latex particles agglutinated, the reaction 
was recorded as positive. A positive and negative con-
trol serum was always included with each test. The 
method of recording the results can be seen in Table 2, 
(page 34) • 
("<) 
("<) 
! 
\ 
Table 1. 
Syringe 
Summary of blood collection, processing and tests performed on the 
various subsamples of blood. 
One Two 
Volume blood 
drawn 5ml. 9ml. 
Subs ample 2ml. 3ml. 
Added to Thrombin/ 
Trayslol EDTA lml. 3.8% sodium citrate solution 
Sub sample 2. 5ml. 2. 5ml. 2.5ml 
2.5ml 1% 
Diluent 2.5ml Celite in 
Tri.s Buff.er Tris buffer 
Subsequent Contact 
Treatment Activation ... • 0 
Tests Platelet Phase 2 Prothrombin Time 
Performed. F.D.P. Count Phase 1 Phase 3 Kaolin-cephalin 
Clot Autocoagulography clotting time. 
Retraction Autocoagulography Fibrinogen 
Control Determination. 
Heparin 
Resistance 
i 
J 
Table 2. Showing the method of recording the 
levels of serum fibrinogen degrada-
products. 
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Serum Dilution Reaction Serum FDP Level 
1:5 Negative Less than lOmicro~rams/ml. 
1:5 Positive 
1:10 Negative 10 to 20 micrograms/ml. 
1:10 Positive 
1:20 Negative 20 to 40 micrograms/ml. 
1:20 Positive 
1:40 Negative 40 to 80 micrograms/ml 
1:40 Pos i tive 
1:80 Negative 80 t o 160 micrograms/ml. 
1:80 Positi ve 
1:160 Negative 160 to 320 micrograms/ ml 
Table 1, (page 3 3), sununarizes the methods 
of blood collection, processing of the various sub-
samples and the tests performed on each of the sub-
samples. 
Methods employed for the Addition of Blood 
and Other Reagents to the Polystyrene Tubes 
and for the Visualization of Fibrin Clot 
Endpoints. 
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For the performance of the phase 1, phase 2, 
phase 3, heparin resistance, autocoagulography and 
autocoagulography control tests, lOml. polystyrene 
tubes, closed with polyethylene caps, were used. 
A ~ inch hole was made in each tube about one third 
of the way down from the stopper, prior to its use. 
The purpose of the hole was to facilitate the addi-
tion of blood (and other reagents} directly into the 
reaction mixtures. (See Figure 10, page 361. 
When performing the clotting tests referred to above, 
the 6 appropriate tubes were held onto a glass plate 
by means of a stout rubber band. The plate, in turn, 
was fixed to a bakelite rod by means of epoxy cement. 
The ends of the rod rested on the edge of the water 
bath during a series of tests. This arrangement 
allowed easy and rapid access to all tubes and per-
mitted simultaneous tilting and observation of all 
the tubes. (See Figure 11, page 37). 
;F~g. 10. 
1 
3 
J::llustra.tin9 the ma.nner ;i.n which · 
blood and other rea9erits were 
added to the plastic test tubes. 
1) The dispensing pipette tip 
2} Plastic test tube containing 
reagents. 
3} Water bath maintained at 37°C. 
4) Top edge of water bath. 
36. 
4 
..._ 
~ 
;Fi.g. 11. 
37 • 
~ 
1 
3 
2 
0 0 0 0 0 0 0 
4 
5 
~ 
Plan view, showing the method o~ hold~n~ 
a number of polystyrene tubes over the 
water bath for the simultaneous perfor-
mance of a number of tests. 
1) Glass plate 
2) Rubber band 
3) Bakelite rod fixed to plate 
4) Top edges of water bath 
5) Polystyrene tubes 
I 
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By means of a mirror placed at an angle in the water 
bath, light from an external light source was directed 
upwards and passed through the tubes under observation. 
This arrangement removed the difficulty, often ex-
perienced, in observing the formation of fibrin clot 
endpoints in tests utilizing whole blood. 
Throughout the study all tests were performed 
in a definite sequence. Phase 1, phase 2, heparin re-
sistance test and phase 3 were performed simultaneously, 
using separate stopwatches for each test. As soon as 
the endpoint was obtained for phase 3, the autocoagulo-
graphy and autocoagulography control tests were commenced 
using separate stopwatches. After the completion of 
these tests, the kaolin-cephalin clotting time and pro-
thrombin time were performed, followed closely by the 
clot retraction study. The estimation of fibrinogen, 
the level of serum fibrino(gen) degradation products 
and the platelet count were carried out last. No 
difficulties were experienced in the simultaneous per-
formance of certain tests referred to above because of 
the wide differences in the clotting times. 
Patients Selected for the Study. 
Patients used in the study were between the 
ages of 35 to 60 years, and were admitted for elective 
surgery, with the exception of patient # 24 who had 
39. 
surgery for a ruptured appendix. The types of sur-
gical procedures together with the numbers of patients 
having a particular surgical operation are shown in 
Table 3,(page 40~ 
The entire spectrum of clotting tests were 
performed on each patient at least once prior to sur-
gery, and when possible, twice before surgery. ~th 
the exception of the kaolin-cephalin clotting time, 
prothrombin time, fibrinogen degradation products, clot 
retraction, fibrinogen and platelet count, all post-
operative results were expressed as a percentage change 
from the pre-operative values, or, when two pre-opera-
tive tests were performed, the percentage change from 
the mean of the pre-operative values. Whenever 
possible, the entire spectrum of clotting tests were 
repeated at two to three day intervals following the 
day of surgery. 
Table 3. 
Number of 
Patients. 
2 
2 
5 
4 
4 
2 
2 
1 
1 
1 
1 
1 
1 
1 
1 
Showing the numbers of patients under-
going various surgical procedures. 
Surgical Procedu re or Event 
40. 
Scheduled, but did not go to surgery 
Minor s u rgery wi th general anaesthes i a 
~astrectomy 
Cholecystectomy 
Splenectomy 
Vagotomy and pyloroplasty 
Laparotomy 
Laparotomy and partial gastrectomy 
Bowel res section 
Removal of large pelvic tumour 
Removal of abdominal t umour 
Right nephrectomy 
Removal of intestinal polyps and 
adhesions 
Thoracotomy 
Appendectomy 
41. 
RESULTS 
REPRODUCIBILITY STUDIES 
In order to determine the precision of the 
tests employed in the study, many of which are ori-
ginal or are modifications of existing techniques, 
the following experiments were performed and the stan-
dard deviation calculated using the following formulae. 
For the calculation of the standard devia-
tion using split samples: 
Standard deviation = ~ J-: 
For the calculation of the standard deviation 
using values obtained from consecutive analyses of a 
single sample: 
Standard deviation = 
1) Reproducibility of the Phase 1 Test. 
Blood samples, collected from 18 healthy persons, 
were each divided into two equal parts. The phase l 
test was performed on each of the subsamples. The mean 
+ 
value was 510 seconds with a standard deviation of -
31 seconds. 
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2) Reproducibility of the Phase 2 Test 
Blood samples, collected from 21 healthy in-
dividuals were each divided into two equal parts. The 
phase 2 test was performed on each subsample. The mean 
value was 210 seconds with a standard deviation of 
+ 
- 10.5 seconds. 
3)-- Reproducibility of the Phase 3 Test. 
Blood samples, collected from 19 healthy persons, 
were each divided into two equal parts. The phase 3 test 
was performed on each subsample. The mean value was 
33.6 seconds with a standard deviation of ± 3.1 seconds. 
4) Reproducibility of the Heparin Resistance 
Test. 
Blood samples collected from 21 healthy persons, 
were each divided into two equal parts. The heparin re-
sistance test was performed on each subsample. The mean 
value was 135 seconds with a standard deviation of ± 7 
seconds. 
5) Reproducibility of the Autocoagulography 
Test. 
Blood samples collected from 16 healthy persons 
were each divided into two equal parts. The autocoagu-
lography test was performed on each subsample. The mean 
value was 16.3 seconds with a standard deviation of 
+ 
- 4 seconds. 
6) Reproducibility of the Autocoagulography 
Control Test. 
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Blood samples, collected from 16 healthy persons, 
were each divided into two equal parts. The autocoagu-
lography control test was performed on each subsample. 
The mean value was 88.4 seconds with a standard deviation 
+ of- 7.8 seconds. 
7) Gravimetric Determination of Fibrinogen as 
Fibrin. 
Plasma, obtained from a single unit of blood 
from the blood abnk, was centrifuged at 2,000 g for 15 
minutes to obtain cell poor plasma. Twenty three con-
secutive deter.minations were performed on 2ml. aliquots 
of the plasma. The mean value was 235 mg./lOOml. 
plasma with a standard deviation of ± 15.5 mg. 
8) Clot Retraction. 
Blood samples, collected from 10 healthy persons, 
were each divided into two equal parts. The clot re-
traction test was performed on each subsample. The 
mean value was 59% with a standard deviation o~ ! 4.5%. 
These values are based on clot retraction figures obtained 
by calculating the % retraction occurring at 60 minutes 
after clotting. 
Variability of Test Results in Single Healthy 
Persons Studied Sequentially. 
Since the study is concerned with the changes 
in clotting activity in individuals during the postopera-
tive period, and since the changes in activity are cal-
44. 
culated using the pre-operative results as a baseline 
for comparison, it is useful to determine the pattern of 
variability occurring in the spectrum of tests under 
normal physiological conditions. Six healthy persons, 
two males and four females, two of whom used oral con-
traceptive pills, were studied sequentially. The 
results are shown in Tables 4 to 9 on pages 45 to 50~ 
Patient Results. 
Patients 1 and 2 were scheduled for surgery and 
were informed of this. Subsequently the surgery was can-
celled. The results of limited sequential testing of 
these patients are shown in Tables 10 and 11 on pages 5l . 
and 5'2 . They were included in the study because of 
the possible influence of psychic factors (related to 
pre-surgical apprehension) on the haemostatic mechanism. 
Patients 3 and 4 both underwent minor surgery 
under general anaesthesia. Patient 3 had a small tumour 
on the upper lip removed and Patient 4 went to surgery for 
the correction of a right hydrocele. Results of limited 
sequential testing are shown in Tables 12 and 13. (See 
pages 53 and 54). Data from both patients were included 
to determine if any pronounced changes in the spectrum of 
clotting tests resulted from the combination of minor 
surgery and general anaesthesia. 
The results of the spectrum of clotting tests 
performed sequentially on the main group of surgical 
Table 4. Showing the results of sequential testing on Normal Male # 1. 
TEST DAY 0 DAY 2 DAY 4 DAY 6 DAY 8 MEAN RANGE 
Phase 1 543 497 565 460 509 514.8 460-565 
Phase 2 223 219 235 190 202 213.8 190-235 
Phase 3 38 36 39 35 37 37 35-39 
Autocoagulography 75 74 78 71 73 74.2 71-78 
-
Autocoagulography 98 88 108 87 83 91.2 83- 108 
Control 
Heparin 128 110 148 113 125 124.8 110-148 
Resistance. 
L-. - ---
,J:::.. 
lJ1 
. 
Table 5. Showi ng the results of sequential testing on Normal Male # 2. 
TEST DAY 0 DAY 2 DAY 4 DAY 6 DAY 8 DAY 10 MEAN RANGE 
Phase 1 501 473 547 519 464 581 514.1 464-581 
Phase 2 209 200 224 197 185 239 209 185-239 
Phase 3 35 32 37 36 31 38 34.8 31-38 
Autocoagu1ography 80 78 83 77 76 85 79.8 76-85 
Autocoagulography 100 98 109 110 99 117 10 5 . 5 . 98-117 
Control 
Heparin 139 114 143 140 117 151 133.5 111-151 
Resistance 
--- -- ----- ·--
~ 
(j 
. 
Table 6. Showing the results of sequential testing on Normal Female # 1. 
(Not using oral contraceptives). 
TEST DAY 0 DAY 2 DAY 4 DAY 6 DAY 8 MEAN RANGE 
Phase 1 494 570 495 540 495 518.8 494- 570 
Phase 2 233 227 216 240 220 227.2 216-240 
Phase 3 36 38 37 38 39 37.6 36-39 
Autocoagulography 67 59 62 64 63 63 59-67 
Autocoagulography 100 99 93 107 96 99 93-107 
Control 
Heparin 12 5 151 139 149 150 142.8 125-151 
Resistance 
-
~ 
~ 
. 
Table 7. Showing the results of sequential testing on Normal Female # 2. 
(Using oral contraceptives. Last pill taken on Day 4). 
TEST DAY 0 DAY 2 DAY 4 DAY 8 MEAN RANGE 
Phasel 527 381 454 690 563 381-690 
Phase 2 258 156 219 257 235 156-307 
Phase 3 29 27 30 42 32 27-42 
Autocoagulography 66 56 63 69 63.5 56-69 
Autocoagulography 103 70 90 112 93.7 70-112 
Control 
Heparin 114 125 119 190 142 119-210 
Resistance 
- ~ ~ 
.t 
0 
. 
Table 8. Showing the results of sequential testing on Normal Female # 3. 
(Using oral cont raceptives). 
TEST DAY 0 DAY 2 DAY 4 DAY 6 DAY 8 MEAN RANGE 
. 
Phase 1 430 442 520 490 355 447.4 355-520 
Phase 2 302 289 263 262 236 270.4 236-302 
Phase 3 30 31 37 39 38 35 30-39 
Autocoagulography 61 54 53 57 59 56.8 53-61 
Autocoagulography 97 90 91 82 86 89.2 82-97 
Control 
Heparin 211 175 191 153 200 186 153-211 
Resistance ~ 
\.0 
. 
Table 9. Showing the results of sequential testing on Normal Female # 4. 
(Not using oral contraceptives) • 
TEST DAY 0 DAY 2 DAY 4 DAY 6 MEAN RANGE 
Phasel 532 527 567 490 529 490-567 
Phase 2 199 240 230 185 213.5 199-240 
Phase 3 34 32 34 34 33.5 32-34 
Autocoagulography 57 62 65 57 60.2 57-65 
Autocoagulography 89 103 98 85 93.7 85-103 
Control 
Heparin 165 150 120 119 138.5 119-165 
Resistance 
1....___ ____ _ --~ ··--- - -- - - - - -
lll 
0 
I 
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Table 10. Show~ng results of sequential testing in 
Pat~ent # 1, who was scheduled b u t did not 
go to surgery. 
TEST Day 0 Day 2 Day 3 Day 5 Mean 
Phase 1 475 464 493 483 478.8 
Phase 2 181 173 194 189 184.3 
Phase 3 36 35 39 38 37.3 
~utocoagulography 51 50 52 49 50.5 
Autocoagulography 
Control 66 64 67 63 65 
Heparin 
Res i stance Test 120 117 119 122 119.5 
Kaol i n-cephalin 
clotting t i me 45 43 45 46 44.7 
Prothrombin Time 12 13 13 12 12.5 
Fi.brinogen Cone. 309 325 330 317 320 
Fibri n. Degrada-
tion products N N N N N 
Platelet Count 321 339 317 299 319 
Clot Retraction 
at 10 minutes 7 5 6 4 
Clot Retraction 
at 20 minutes 11 14 12 10 
Clot Retraction 
at 30 minutes 41 39 43 38 
Clot Retraction 
at 60 mi nutes 67 65 66 66 
Median Retractive 
rndex. 
Maximum Retractive 
Activity Time 30 60 30 30 
52. 
Table 11. Showing the results of sequential testing 
in Patient # 2, who was scheduled but did 
not go to surgery. 
TEST Day 0 Day 2 Day 4 Mean. 
Phase 1 375 361 387 384.3 
Phase 2 130 133 125 129.3 
Phase 3 38 40 37 38.3 
Autocoagulography 51 53 49 51 
Autocoagulography 
Control 59 60 57 58.6 
Heparin 
Resistance Test 105 99 103 102.3 
Kaolin-cephalin 
clotting time 41 43 45 43 
Prothrombin Time 12 13 13 12.6 
Fibrinogen Cone. 362 384 351 365 
Fibrin. Degrada-
tion Products N N N 
Platelet 
Count 291 330 319 313 
Clot Retraction 
at 10 minutes 3 5 2 
Clot Retraction 
at 20 minutes 29 31 30 
Clot Retraction 
at 30 minutes 47 44 46 
Clot Retracti on 
at 60 minutes 61 59 58 
Table 12. Showing the results of limited 
sequential testing in Patient # 3 who 
had a small tumour on the l i p removed 
under general anaesthesia. 
TEST Pre-operative Day 1 
Result Post-operative 
r 
Phase 1 605 645 
Phase 2 185 180 
Phase 3 41 39 
Autocoagulography 52 53 
Autocoagulography 
Control 58 59 
Heparin 
Resi.stance Test 112 115 
Kaol.in-cephalin 
clott.ing time 43 44 
Prothromb.in Time 13 13 
F i brinogen Cone. 207 223 
F i bri.n. Degrada-
t .ion Products N N 
Platelet Count 311 328 
Clot Retraction 
a t 10 minutes 5 7 
Clot Retraction 
at 20 minutes 16 19 
Clot Retraction 
at 30 minutes 29 33 
Clot Retraction 
at 60 minutes 46 48 
Medi an Retractive 
Index - -
Max imum Retractive 
Activity Time 60 60 
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Table 13. Showing the results of limited 
sequential testing in Patient # 4 
who underwent surgical correction of 
a right hydrocele. 
TEST Pre-operative Postoperative 
Day 0 Day 3 
Phase 1 464 431 420 
Phase 2 110 115 109 
Phase 3 41 37 39 
Autocoagulography 39 41 39 
Autocoagulography 43 44 42 
Hepari n 
Resistance Test 159 161 165 
Kaolin-cephali.n 
clotting time 41 43 41 
Prothrombin Time 13 13 13 
Fibrinogen Cone. 319 330 334 
F i brin. Degrada-
tion Products. N N N 
Platelet Count 289 301 288 
Clot Retraction 
at 10 minutes 2 3 10 
Clot Retraction 
at 20 minutes 16 18 29 
Clot Retraction 
at 30 minu tes 36 39 48 
Clot Retraction 
at 60 minutes 55 53 60 
Median Retractive 
I n dex . 
- - -
Maxi mum Retractive 
Ac tivity Time 30 30 30 
54. 
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patients (#5 to #29), are shown individually in Tables 
14 to 38 (pages 56 to 80), and as a group for each test, 
in Figures 12 to 21 (pages 81 to 90). 
TABLE 14. Showing the results of sequential testing for Patient # 5. 
'Pre' refers to preoperative tests and the numerals following 
TEST 
Phase 1 
Phase 2 
Phase 3 
H.R.T. 
A.C.G. 
A.C.G.C. 
K.C.C.T. 
P.T. 
F.D.P. 
G.E.F. 
Plats. 
C.R. 10 
C.R. 20 
C.R. 30 
C. R. 60 
.LM.R.I. 
M.R.A.T. 
the preoperative mean column indicate days following cholecystectomy. 
Columns headed '%' show the percentage change from the pre-
operative mean. 
PRE PRE PRE X 1 % 3 % 5 % 7 % 
- 586 586 406 31 416 29 564 4 532 9 
- 220 220 165 25 132 40 116 47 158 28 
- 40 40 38 5 35 13 36 10 35 13 
- 128 128 124 3 85 17 114 11 90 30 
- 45 45· 45 0 43 4 47 4 45 o l 
- - - - - - - - - - -
- 44 44 41 40 39 41 
- 13 13 12 12 13 14 
- Neg Neg 10-20 Neg Neg Neg 
- 281 281 275 290 354 403 
- 197 197 200 189 253 301 
- 0 0 1 5 4 2 
- 3 3 12 17 22 12 
- 18 18 48 40 44 20 
- 51 51 69 59 58 55 
- 58 58 33 45 43 55 
- 60 60 30 30 30 60 
I 
- -- - -
(See Appendix for meanings of abbreviations and units of measurement) 
U1 
0"1 
TABLE 15 . Showing the r esults of sequential testing for Patient # 6. 
'Pre' refers t o preoperative tests and the numerals following 
the preoperat ive mean column indicate days following bowel 
resection. Columns headed '%' show the percentage change 
from the preoperative mean. 
TEST PRE PRE PRE X 1 % 3 % 5 % 7 
Phase 1 478 466 472 380 19 378 20 298 37 309 
Phase 2 190 200 195 141 28 121 38 112 43 119 
Phase 3 36 34 35 30 14 29 20 30 14 33 
H.R.T. 165 155 160 150 6 106 34 65 59 75 
A.C.G. 50 46 48 46 4 42 12 45 6 47 
A.C.G.C. 68 58 63 61 3 52 17 50 21 50 
K.C.C.T. 42 42 42 40 40 38 40 
P.T . 12 - 12 14 15 13 14 
F.D.P. Neg Neg Neg 10-20 Neg Neg Neg 
G.E . F. 330 - 330 359 434 559 601 
Pl ats. 215 - 215 183 197 241 361 
C. R. 10 2 - 2 6 4 6 8 
C.R. 20 33 - 33 25 17 42 40 
C.R. 30 48 - 48 42 37 50 51 
C. R. 60 64 - 64 53 53 64 60 
M.R.I. 34 - 34 52 54 30 26 
M.R.A.T. 20 . - 20 20 30 20 20 
(See Appendix for meanings o~ abbreviations and units of measurement) 
% 
35 
39 
6 
53 
2 
21 
I 
ll1 
-....J 
TABLE 16. Showing the results of sequential testing for Patient# 7. 
'Pre' refers to preoperative tests and the numerals following 
the preoperative mean column indicate days following removal 
of a large pelvic tumour. Columns headed '%' show the 
percentage change from the preoperative mean. 
TEST PRE PRE PRE X 2 % 4 % 7 % 9 
Phase l 301 370 335 250 25 229 32 263 21 260 
Phase 2 125 146 136 98 28 78 43 115 15 116 
Phase 3 24 26 25 23 8 20 20 23 8 26 
H.R.T. 112 108 110 84 24 70 36 85 23 82 
A.C.G. 50 50 50 46 8 42 16 44 12 43 
A.C.G.C. 59 69 64 53 17 51 20 53 17 54 
K.C.C.T. 38 40 39 37 38 41 40 
P.T. 13 15 14 14 13 14 14 
F.D.P. Neg Neg 10-20 10-20 Neg Neg 
G.E.F. 541 - 541 579 636 784 839 
Plats. 401 - 401 417 509 616 670 
C. R. 10 4 - 4 5 7 6 3 
C.R. 20 33 - 33 35 42 39 29 
C.R. 30 49 - 49 52 58 53 48 
C.R . 60 62 - 62 64 66 64 60 
M.R . I . 32 - 32 24 25 27 36 
M.R.A.T. 20 - 20 20 20 20 20 
----- ~ 
(See Appendix for meanings of abbreviations and units of measurement ) 
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14 
16 
I 
Ul 
00 
TABLE 17. Showing the results of sequential testing for Patient # 8. 
TEST 
Phase 1 
Phase 2 
Phase 3 
H.R.T. 
A.C.G. 
A. C.G . C. 
K.C.C.T. 
P.T. 
F.D.P . 
G.E.F. 
Plats. 
C.R. 10 
C. R. 20 
C . R. 30 
C. R. 60 
M.R.I . 
M. R.A . T. 
'Pre' refers to preoperative tests and the numerals fol l owing 
the preoperative mean column indicate days following gastrectomy. 
Columns headed '%' show the percentage change from the pre-
operative mean. 
PRE PRE PRE )( 1 % 3 % 4 % 6 % 8 % 10 
- 487 487 380 22 360 26 410 16 389 20 374 23 393 
":"' 230 230 214 7 160 30 169 27 175 24 169 27 172 
- 25 25 26 4 25 0 29 16 27 8 26 4 24 
- 95 95 92 3 80 16 76 20 75 21 79 17 84 
- 72 72 80 11 61 15 68 6 66 8 64 11 70 
- 107 107 104 3 75 30 82 23 84 21 82 23 109 
- 43 43 42 39 35 36 40 41 
- 12 12 14 15 13 15 13 13 
- N N n.o-20 20-40 10-20 N N N 
- 489 489 522 601 716 773 685 676 
- 260 260 195 371 346 593 599 579 
- 5 5 7 3 1 4 6 3 
- 25 25 28 24 20 24 25 26 
- 41 41 43 39 36 41 40 39 
- 51 51 52 50 47 53 52 49 
- 58 58 55 60 52 56 
- 20 20 20 20 20 20 20 20 
(See Appendix of meanings of abbreviations and units of measurement ) 
% 
19 
25 
4 
12 
3 
2 
U1 
1..0 
TABLE 18. Showing the results of sequential testing for Patient # 9. 
'Pre' refers to preoperative tests and the numerals following 
the preoperative mean column indicate days following vagotomy 
and pyloroplasty. Columns headed '%' show the percentage 
change from the preoperative mean. 
TEST PRE PRE PRE X 1 ~ 3 % 5 % 7 % 9 % 10 % 
Phase 1 458 424 441 396 10 385 13 398 10 430 2 375 15 368 17 
Phase 2 158 130 144 175 22 115 20 113 22 131 9 127 12 106 26 
Phase 3 23 25 24 24 0 40 67 38 58 23 4 25 4 23 4 
H.R.T. 116 100 108 129 19 100 8 89 18 90 17 116 7 83 23 
A.C.G. 53 51 52 52 0 45 13 48 8 47 10 41 21 45 13 
A.C.G.C. 59 55 57 51 10 52 9 52 9 51 10 46 19 45 21 
K.C.C.T. 51 49 50 41 42 47 40 40 41 
P.T. 14 12 13 13 15 13 13 13 13 
F.D.P. N - N N 10-2( N N N N 
G.E.F. 363 367 365 391 481 509 700 815 801 
Plats. 301 325 313 298 300 359 523 448 420 
C.R. 10 0 - 0 0 0 9 - 3 1 
C.R. 20 1 - 1 2 3 28 - 25 21 
C.R. 30 9 - 9 13 34 40 - 42 40 
C.R. 60 46 - 46 48 54 52 - 56 58 
M.R.I. - - - - 55 55 - 47 46 
M.R.A.T. 60 - 60 60 30 20 - 20 20 
(See Appendix for meanings of abbreviations and units of measurement) 
11 
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113 
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44 
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N 
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TABLE 19. Showing the results of sequential testing for Patient # 10. 
'Pre' refers to preoperative tests and the numerals following 
TEST 
Phase 1 
Phase 2 
Phase 3 
H.R.T. 
A.C.G. 
A.C.G.C. 
K.C.C.T. 
P.T. 
F.D.P. 
G.E.F. 
Plats. 
C.R. 10 
C.R. 20 
C.R. 30 
C.R. 60 
M.R.I. 
M.R.A.T. 
the preoperative mean column indicate days following thoracotomy. 
Columns headed '%' show the percentage change from the pre-
operative mean. 
PRE PRE PRE X 1 % 4 % 6 % 8 % 10 
519 475 497 376 24 370 25 390 21 420 15 347 
240 228 234 212 9 151 35 153 35 157 33 175 
25 23 24 26 8 25 4 26 8 29 21 25 
97 97 97 92 5 80 18 77 21 75 23 78 
75 69 72 81 12 61 15 65 10 68 6 64 
109 107 108 105 3 75 31 79 27 82 24 82 
36 40 38 38 34 35 34 42 
11 11 11 11 12 13 13 14 
N - N N 10-20 N N N 
620 - 620 654 850 925 1168 1041 
250 190 220 136 325 369 410 440 
1 - 1 7 12 11 13 12 
4 - 4 25 31 32 33 35 
11 - 11 38 46 48 45 47 
32 - 32 50 60 61 57 60 
- - - 60 40 35 43 37 
60 - 60 20 20 20 20 20 
(See Appendix for meanings of abbreviations and units of measurement) 
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TABLE 20. Showing the results of sequential testing for Patient # 11. 
TEST 
Phase 1 
Phase 2 
Phase 3 
H.R.T. 
A.C.G. 
A.C.G.C. 
K.C.C . T. 
P.T. 
F.D.P. 
G.E.F . 
Plats. 
C. R. 10 
C.R. 20 
C. R. 30 
C.R. 60 
M.R.I. 
'Pre' refers to preoperative tests and the numerals following 
the preoperative mean column indicate days following gastrectomy. 
Columns headed '%' show the percentage change from the pre-
operative mean. 
PRE PRE PRE X 1 % 4 % 6 % 8 % 
490 440 465 401 14 466 0 435 6 345 26 
195 179 187 175 6 230 23 200 7 173 7 
29 33 31 41 32 36 16 35 13 34 10 
90 84 87 62 29 90 3 70 20 75 14 
55 51 53 54 2 56 6 50 6 59 11 
78 74 76 78 3 88 16 77 1 79 4 
35 37 36 53 41 33 35 
11 11 11 16 14 12 12 
N N N N 40-80 20-40 10-20 
543 483 513 362 340 330 478 
174 - 174 134 165 294 330 
4 - 4 6 20 25 21 
26 - 26 27 35 41 36 
36 - 36 43 50 53 52 
45 - 45 58 65 64 62 
- - - 44 30 27 29 
~ M.R.A.T. 20 - 20 20 10 10 10 
------ -
(See Appendix for meanings of abbreviations and units of measurement ) 
0) 
!\) 
TABLE 21. Showing the results of sequential testing for Patient # 12. 
'Pre' refers to preoperative tests and the numerals fo l lowing 
the preoperative mean column indicate days following right 
nephrectomy. Columns headed '%' show the percentage change 
from the preoperative mean. 
TEST PRE PRE PRE X 2 % 4 % 6 % 8 % 12 ~ 0 14 
Phase l 503 543 523 410 22 480 8 464 11 365 30 379 27 408 
Phase 2 239 249 244 205 16 255 5 253 4 162 34 179 27 211 
Phase 3 33 - 33 34 3 32 3 37 12 43 30 33 0 32 
H.R.T. 98 - 98 77 21 82 16 85 13 76 22 77 21 78 
A.C.G . 61 - 61 61 0 56 8 75 30 63 3 67 10 72 
A.C . G.C. 109 - 109 92 16 110 1 113 4 79 28 86 21 108 
K.C.C.T. 36 - 36 34 36 34 34 34 34 
P. T. 13 - 13 14 14 13 14 14 13 
F.D.P. N - N 10- 20 10-20 N N N N 
G.E.F. 681 - 681 769 963 1131 888 813 708 
Plats. 138 - 138 101 124 266 377 400 391 
C.R. 10 0 - 0 1 3 8 8 12 14 
C.R. 20 5 - 5 2 18 25 26 24 28 
C.R. 30 23 - 23 27 37 39 42 44 45 
C.R. 60 46 - 46 52 54 50 56 58 61 
M.R.I . - - - 48 47 60 47 43 39 
M.R.A.T. 60 0 60 60 30 30 30 30 30 
(See Appendix for meanings of abbreviations and units of measurement) 
% 
22 
14 
3 
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18 
1 
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TABLE 22 . Showing the results of sequential testing for Patient # 13. 
TEST 
Phase 1 
Phase 2 
Phase 3 
H.R.T. 
A. C.G . 
A.C.G.C . 
K.C.C.T. 
P . T. 
F.D.P. 
G.E.F . 
Plats. 
C. R. 10 
C. R. 20 
C.R . 30 
C.R. 60 
M.R.I. 
M.R.A . T. 
'Pre' refers to preoperative tests and the numerals following 
the preoperative mean column indicate days following cholecystectomy. 
Columns headed '%' show the percentage change from the preoperative 
mean. 
PRE PRE PRE X 2 % 4 % 6 % 8 2, 0 
- 430 430 405 6 328 24 447 4 401 7 
- 197 197 202 3 182 8 205 4 199 1 
- 35 35 41 17 33 6 35 0 34 3 
- 129 129 132 2 113 12 131 2 122 5 
- 72 72 52 28 60 17 62 14 59 18 
- 106 106 80 25 75 29 93 12 83 22 
- 37 37 34 38 39 36 
- 13 13 14 13 12 12 
- N N 10-20 N N N 
- 352 352 451 570 610 653 
- 230 230 171 220 319 361 
- 12 12 6 11 13 11 
- 36 36 32 29 32 32 
- 48 48 50 44 46 48 
- 58 58 59 56 59 60 
- 36 36 30 46 40 35 
- 20 20 20 20 20 20 
(See Appendix for meanings of abbreviations and units of measurement) 
0'1 
~ 
TABLE 23. Showing the results of sequential t esting for Patient # 14. 
'Pre' refers to preoperative t ests and the numerals follow i ng 
the preoperative mean column indicate days following laparotomy 
and removal of intestinal polyps and adhesions. Columns headed 
'%' show the percentage change from the preoperative mean. 
TEST PRE PRE PRE X 1 % 3 2, 0 4 % 5 % 6 % 8 
Phase 1 460 560 510 ~83 25 415 19 386 24 370 27 393 23 437 
Phase 2 199 233 216 182 16 170 21 173 20 185 14 142 34 170 
Phase 3 35 35 35 38 9 37 6 38 9 35 0 35 0 33 
H.R . T. 138 148 143 1151 6 97 32 126 12 110 23 94 34 124 
A.C.G. 55 53 54 58 7 53 2 54 0 40 26 52 4 56 
A.C.G.C. 79 83 81 82 1 81 0 . 75 7 63 22 66 19 79 
K.C.C.T. 47 45 46 42 41 42 41 39 46 
P.T. 12 12 12 13 11 12 13 11 12 
F.D.P. N - N N 10-20 N N N N 
G.E.F. 366 - 366 360 549 507 502 438 306 
Plats. 308 364 336 ~ 78 231 310 413 473 515 
C.R. 10 16 - 16 10 6 4 12 17 14 
C.R. 20 33 - 33 30 24 22 32 36 32 
C.R. 30 59 - 59 55 50 47 52 54 58 
C.R. 60 70 - 70 63 58 54 60 59 66 
M.R.I . 26 - 26 27 30 24 29 27 27 
M.R.A.T . 30 - 30 30 30 30 20-30 20 30 
% 
14 
21 
6 
13 
4 
2 
- --- -- ----------- - -~---
(See Appendix for meanings of abbreviations and units of measurement ) 
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TABLE 24. Showing the results of sequential testing for Patient # 15. 
TEST 
Phase 1 
Phase 2 
Phase 3 
H.R.T. 
A.C.G. 
A.C.G.C. 
K.C.C.T. 
P.T. 
F.D.P. 
G.E.F. 
Plats. 
C. R. 10 
C.R. 20 
C.R. 30 
C. R. 60 
M.R.I. 
M.R.A.T. 
L___. ___ 
'Pre' refers to preoperative tests and the numerals following 
the preoperative mean column indicate days following splenectomy. 
Columns headed '%' show the percentage change from the pre-
operative mean. 
PRE PRE PRE X 1 % 3 % 5 % 7 % 
380 401 390 358 8 360 7 371 5 360 7 
166 168 167 135 19 117 30 120 28 116 30 
50 48 49 40 22 50 2 51 4 49 0 
139 - 139 90 32 77 42 94 29 92 31 
. 53'. 57 55 51 8 56 1 54 3 55 1 
57 - 57 57 0 52 9 55 4 55 4 
46 - 46 53 15 49 6 45 2 44 4 
13 13 13 15 19 18 16 
N N N 10-20 N 
301 301 290 339 401 519 
277 277 270 339 414 503 
3 3 8 16 16 18 
12 12 20 30 36 38 
33 33 40 49 48 53 
59 59 60 63 60 66 
49 49 45 32 35 28 
60 60 30 30 20 20 
-------- - - --
(See Appendix £or meanings of abbreviations and units of measurement) 
I 
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TABLE 25. Showing the results o~ sequential testing for Patient # 16. 
'Pre ' refers to preoperative tests and the numerals following 
TEST 
Phase 1 
Phase 2 
Phase 3 
H.R.T. 
A.C.G . 
A.C.G.C. 
K.C.C.T. 
P . T. 
F.D.P. 
G.E.F. 
Plats. 
C. R. 10 
C. R. 20 
C. R. 30 
C.R. 60 
M.R.I. 
M.R . A.T . 
...._,_ _ ___ ____ 
the preoperative mean column indicate days following cholecystectomy. 
Columns headed '%' show the percentage change from the preoperative 
mean. 
PRE PRE PRE X 1 % 3 % 5 % 7 % 
561 599 580 457 21 471 19 493 15 469 19 
202 238 220 171 22 129 41 119 46 143 35 
41 39 40 37 7.5 34 15 37 7.5 35 12.5 
- - 125 121 2 88 30 109 13 92 26 
47 47 47 44 6 48 2 46 2 45 4 
69 71 70 65 7 62 11 68 3 67 4 
43 45 44 42 4.5 40 9 39 11 38 14 
13.5 12.5 13 12 12 13 14 
N 10-20 10-20 N N 
221 239 230 217 6 264 15 331 44 409 78 
201 201 223 11 269 34 331 65 427 112 
0 0 2 5 5 4 
5 5 14 19 22 19 
21 21 39 40 44 39 
54 54 56 58 57 54 
56 56 49 46 44 52 
60 60 30 30 30 30 
(See Appendix for meanings of abbreviations and units of measurement) 
"' -....)
TABLE 26. Showing the results of sequential t esting for Patient# 17. 
'Pre' refers to preoperative tests and the numerals following 
the preoperative mean column indicate days following sub-total 
gastrectomy. Columns headed '%' show the percentage change 
from the preoperative mean. 
TEST PRE PRE PRE X 1 % 3 % 4 % 6 % 8 % 10 
Phase 1 457 517 487 361 26 352 28 400 18 373 23 359 26 401 
Phase 2 236 206 221 209 5 152 31 159 28 161 27 158 28 174 
Phase 3 27 29 28 30 7 28 0 30 7 26 7 25 11 23 
H.R.T. 99 91 95 90 5 78 18 74 22 76 20 78 18 83 
A.C.G. 74 76 75 80 7 63 16 67 11 65 13 63 16 68 
A.C.G.C. 110 104 107 101 6 78 27 81 24 82 23 81 24 93 
K.C.C.T. 41 43 42 41 2 38 9 36 14 36 14 39 7 42 
P.T . 12 12 12 14 15 14 15 14 13 
F.D . P. N 10-20 20-40 10-20 N N 
G. E. F. 431 452 441 452 2 519 18 639 45 702 59 773 75 791 
plats. 231 231 219 5 235 2 343 15 378 64 424 83 561 
C.R. 10 5 5 7 3 5 4 3 
C.R . 20 25 25 26 25 26 27 26 
C. R. 30 49 49 47 42 39 41 39 
C. R. 60 51 51 50 51 49 52 49 
M.R.I. 46 46 60 40 41 
M.R.A.T. 20 20 30 20 20 20 20 
(See Appendix for meanings of abbreviations and units of measurement ) 
% 
18 
21 
18 
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13 
0 
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TABLE 27. Showing the results of sequential testing for Patient # 18. 
'Pre' refers to preoperative tests and the numerals following 
the preoperative mean column indicate days following vagotomy. 
Columns headed '%' show the percentage change from the pre-
operative mean. 
TEST PRE PRE PRE X 1 % 3 % 5 % 7 % 9 % 10 
Phase 1 431 473 452 371 18 369 18 383 15 402 11 350 22 331 
Phase 2 142 164 153 159 4 109 29 108 29 115 24 114 29 103 
Phase 3 26 26 27 27 4 38 46 36 38 25 4 24 8 22 
H.R.T. 104 116 110 117 16 98 11 83 24 90 18 101 8 84 
A.C.G. 55 61 58 57 2 43 26 45 22 46 21 43 26 46 
A.C . G. C. 61 67 64 62 3 62 3 63 2 61 1 52 19 50 
K.C.C.T. 50 - 50 46 8 47 6 46 8 45 10 43 14 43 
P.T. 13 - 13 13 15 14 13 13 12 
F.D.P. 
- - N N 10-20 N N N N 
G.E.F . 351 - 351 378 8 431 15 497 42 563 60 621 77 598 
Plats. 291 - 291 298 2 313 7 371 27 470 61 469 61 474 
C. R ... 10 - 0 -o 0 2 3 1 1 3 
C.R. 20 - 6 6 4 9 13 14 17 11 
C.R. 30 - 31 31 24 32 34 38 41 34 
C. R. 60 - 54 54 51 52 55 56 59 55 
M.R.I. - 54 54 59 57 52 50 45 52 
M.R .A. T. - 30 30 60 30 30 30 30 30 
'- - ---~ - ------ -
(See Appendix for meanings of abbreviations and units of measurement) 
% 
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TABLE 28. Showing the results of sequential testing for Patient# 19. 
TEST 
Phase 1 
Phase 2 
Phase 3 
H.R.T. 
A.C.G. 
A.C.G.C. 
K.C.C.T. 
P.T. 
F.D.P. 
G.E.F. 
Plats. 
C. R. 10 
C.R. 20 
C.R. 30 
C. R. 60 
M.R.I. 
M.R.A.T. 
'Pre' refers to preoperative tests and the numerals following 
the preoperative mean column indicate days following cholecystectomy. 
Columns headed '%' show the percentage change from the preoperative 
mean. 
PRE PRE PRE X 1 % 4 % 6 % 8 % 
510 482 496 413 17 450 9 423 15 398 20 
149 179 164 151 8 185 13 169 3 161 2 
33 33 33 40 21 34 3 32 3 31 6 
89 101 95 69 27 94 1 72 24 73 23 
- - 55 56 2 54 2 50 9 49 11 
- - 78 77 1 81 4 76 3 77 1 
34 36 35 47 34 37 6 34 3 34 3 
11 11 11 15 13 13 12 
- - N N 20-40 40-80 10-20 
535 - 535 417 22 434 19 490 8 549 3 
183 - 183 131 38 191 4 233 27 347 90 
6 - 6 8 17 21 20 
24 - 24 26 34 40 37 
38 - 38 42 50 55 49 
49 - 49 53 59 59 60 
- - - 52 30 26 33 
20 - 20 60 10 10 10 
~----- -- ----
-
(See Appendix for meanings of abbreviations and units of measurement) 
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TABLE 29. Showing the results of sequential testing for Patient # 20. 
'Pre' refers to preoperative tests and the numerals following 
the preoperative mean column indicate days following laparotomy. 
Columns headed '%' show the percentage change from the pre-
operative mean. 
TEST PRE PRE PRE X 1 % 2 % 4 % 6 % 8 
Phase 1 448 490 469 413 12 381 19 319 32 391 17 337 
Phase 2 - - 181 182 0 152 16 134 36 177 22 171 
Phase 3 35 37 36 42 17 35 3 31 14 34 6 32 
H. R.T. 139 121 130 430 0 122 6 115 11 126 3 117 
A.C.G. - - 79 73 8 61 23 65 18 63 20 60 
A.C.G.C. 119 103 111 87 22 74 33 72 35 75 32 73 
K.C.C.T. 37 37 37 35 5 38 3 39 5 38 3 36 
P.T. 13 13 13 13 14 14 13 12 
F.D.P. N N 10-20 N N N N 
G.E.F. - 360 360 411 14 471 31 539 50 624 73 679 
Plats. - 201 201 181 10 193 4 254 26 371 84 439 
C.R. 10 - 10 10 7 - 12 9 8 
C. R. 20 - 37 37 33 - 35 40 37 
C.R. 30 - 49 49 45 - 49 52 29 
C. R. 60 - 61 61 57 - 62 63 57 
M.R.I. 
- 32 32 36 - 32 28 43 
M.R.A.T. - 20 20 20 - 30 20 20 
.......______ 
---~-
(See Appendix for meanings of abbreviations and units of measurement) 
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TABLE 30. Showing the results of sequential testing for Patient # 21. 
'Pre' refers to preoperative tests and the numerals following 
the preoperative mean column indicate days following removal 
of an abdeominal tumour. Columns headed '%' show the percentage 
change from the preoperative mean. 
TEST PRE PRE PRE X 1 % 2 % 3 % 5 % 7 
Phase 1 361 398 379 309 18 287 24 269 29 281 26 272 
Phase 2 143 119 131 109 17 100 24 97 26 105 20 104 
Phase 3 40 34 37 29 22 26 30 22 40 24 35 24 
H.R.T. 98 104 101 85 16 71 30 62 39 65 36 66 
A.C.G. - - 53 43 19 39 26 36 32 41 23 38 
A.C.G.C. - - 70 58 17 52 50 14 54 23 53 
K.C.C.T. 41 43 42 39 7 39 7 38 12 40 5 41 
P.T. 14 14 14 15 14 15 13 14 
F.D.P. - N N N N 10-20 N N 
G.E.F. 
- 489 489 501 2.4 507 4 569 16 636 30 709 
Plats. - 434 434 411 5 436 0 574 32 689 59 730 
C. R. 10 - 4 4 4 - 10 8 11 
C. R. 20 - 12 12 12 - 20 21 29 
C.R. 30 - 39 39 33 - 42 44 48 
C.R. 60 - 63 63 59 - 65 62 59 
M.R . I. - 43 43 50 - 40 40 35 
M.R.A.T. 
- 30 30 60 - 60 30 30 
(See Appendix for meanings of abbreviations and units of measurement) 
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TABLE 31. Showing the results of sequential testing for Patient # 22. 
TEST 
Phase 1 
Phase 2 
Phase 3 
H.R.T. 
A.C.G. 
A.C.G.C. 
K.C.C.T. 
P.T. 
F.D.P. 
G.E.F. 
Plats. 
C.R. 10 
C. R. 20 
C.R. 30 
C.R. 60 
M.R.I. 
M.R.A.T. 
'Pre' refers to preoperative tests and the numerals following 
the preoperative mean column indicate days following splenectomy. 
Columns headed '%' show the percentage change from the pre-
operative mean. 
PRE PRE PRE X 1 % 2 % 3 % 5 % 7 % 9 
- 458 458 413 10 379 17 321 30 359 22 373 18 350 
-
194 194 170 12 159 18 161 17 173 11 179 8 160 
- 50 50 42 16 40 20 47 6 49 2 47 6 52 
- 133 133 90 32 81 39 77 42 94 29 90 32 87 
- 59 59 52 12 54 8 57 3 57 3 52 12 53 
- 61 61 60 2 55 8 56 16 57 6.5 55 10 56 
- 46 46 53 51 49 47 46 48 
- 13 13 15 17 19 18 16 14 
- N N N N N N N N 
- 301 301 290 - 393 456 439 501 
- 279 279 270 265 339 401 519 
- 6 6 9 - 16 16 18 
- 18 18 17 - 30 36 38 
- 42 42 40 - 49 48 53 
- 60 60 57 - 63 60 66 
- 43 43 47 - 47 35 28 
- 30 30 30 - 20 20 20 
--·-
I.... 
(See Appendix for meanings of abbreviations and units of measurement) 
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TABLE 32. Showing the results of sequential tes t ing for Patient # 23. 
'Pre' refers to preoperative tests and the numerals following 
the preoperative mean column indicate days following laparotomy. 
Columns headed '%' show the percentage change from the pre-
operative mean. 
TEST PRE PRE PRE X 1 % 3 % 5 % 7 % 
Phase 1 504 - 504 470 7 403 20 393 22 441 12 
Phase 2 219 - 219 184 16 162 26 158 28 179 18 
Phase 3 30 - 30 28 6 27 10 29 3 31 3 
H.R.T. 120 - 120 109 9 89 26 71 41 88 27 
A.C.G. 55 - 55 45 18 40 27 40 27 43 22 
A.C.G.C. 73 - 73 67 8 62 15 60 18 68 7 
K.C.C.T. 46 - 46 44 42 43 46 
P.T. 12 - 12 13 14 13 13 
F.D.P . N - - N 10-20 N N 
G.E.F . 319 - 319 316 336 430 561 
Plats. 271 - 271 283 291 353 419 
C. R. 10 0 - 0 1 5 7 5 
C.R. 20 5 - 5 7 13 13 15 
C.R. 30 31 - 31 29 33 41 44 
C.R. 60 51 - 51 53 56 59 56 
M.R . I. 58 - 58 56 52 45 45 
M.R . A.T. 30 - 30 60 60 30 30 
(See Appendix for meani ngs of abbreviati ons and units of measurement) 
-....! 
~ 
TABLE 33. Showing the results of sequential testing for Patient # 24. 
'Pre' refers to preoperative tests and the numerals fol l owing 
the preoperative mean column indicate days following surgery 
for a ruptured appendix. Columns headed '%' show the percentage 
change from the preoperative mean. 
TEST PRE PRE PRE X 1 % 3 S: 0 5 % 7 % 
Phase 1 398 - 398 370 7 309 22 354 11 383 4 
Phase 2 194 - 194 162 16 141 27 161 16 181 7 
Phase 3 31 - 31 29 6 28 10 28 10 32 3 
H.R.T. 125 - 125 103 18 87 30 85 32 96 23 
A.C.G. 61 - 61 57 6 49 20 53 13 58 5 
A.C.G.C. 98 - 98 83 15 76 22 79 19 87 11 
K.C.C.T. 47 - 47 45 43 41 44 
P.T. 13 - 13 15 15 14 14 
F.D.P. - - N N N N N 
G. E. F. 360 - 360 369 397 451 483 
Plats. 217 - 217 201 231 269 288 
C. R. 10 7 - 7 8 - 11 9 
C.R. 20 19 - 19 17 - 24 28 
C. R. 30 42 - 42 40 - 45 43 
C. R. 60 54 - 54 53 - 56 51 
M.R.I. 50 - 50 53 - 43 55 
M.R.A.T. 30 - 30 30 - 30 20 
(See Appendix for meanings of abbreviations and units of measurement ) 
-....] 
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TABLE 34. Showing the results of sequential testing for Patient # 25 . 
'Pre' refers to preoperative tests and the numerals following 
the preoperative mean column indicate days following laparotomy 
and gastrectomy. Columns headed '%' show the percentage change 
from the preoperative mean. 
TEST PRE PRE PRE X 1 % 3 2, 0 5 % 7 
Phase 1 361 425 393 353 10 323 18 330 16 312 
Phase 2 135 141 138 121 12 110 20 118 14 112 
Phase 3 40 30 35 25 28 23 34 26 26 25 
H.R.T. 99 115 107 85 21 62 42 71 34 69 
A. C.G. 63 49 55 41 27 38 32 42 25 40 
A. C. G.C. 78 62 70 52 26 49 30 55 21 52 
K.C.C.T. 40 42 41 39 38 42 42 
P.T. 14 14 14 15 15 14 15 
F.D.P . N - N N 10-20 N N 
G. E.F. 485 - 485 499 537 658 663 
Pl ats . 410 - 410 370 390 521 619 
C. R. 10 4 - 4 4 10 9 5 
C. R. 20 12 - 12 7 19 21 20 
C. R. 30 39 - 39 31 42 43 46 
C. R. 60 63 - 63 62 66 62 65 
M.R . I . 43 - 43 48 40 41 36 
M. R.A . T. 30 - 30 60 60 30 30 
(See Appendix for meanings of abbreviations and units of measurement) 
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TABLE 35. Showing the results of sequential testing for Pat ient # 26. 
'Pre' refers to preoperative tests and the numerals following 
TEST 
Phase 1 
Phase 2 
Phase 3 
H.R.T. 
A.C.G. 
A.C.G.C. 
K. C.C .T. 
P.T . 
F.D.P. 
G. E. F . 
Plats. 
C. R. 10 
C. R. 20 
C. R. 30 
C.R. 60 
M.R : I. 
M.R.A . T. 
the preoperative mean column indicate days following splenectomy. 
Columns headed '%' show the percentage change from the pre-
operative mean. 
PRE PRE PRE X 1 % 3 % 5 % 7 % 
380 401 390 358 8 360 8 371 5 360 8 
166 168 167 135 19 117 30 120 28 117 30 
50 48 49 40 18 50 2 51 4 49 0 
139 127 133 90 26 77 42 94 29 92 31 
55 57 56 51 9 56 0 54 4 55 2 
57 59 58 57 2 52 10 55 5 55 5 
46 46 46 53 49 45 44 
13 13 13 15 19 18 16 
N - N N N N N 
301 - 301 290 393 456 439 
277 - 277 270 339 401 519 
3 - 3 8 16 16 18 
12 - 12 20 30 36 38 
33 - 33 40 49 48 53 
59 - 59 60 63 60 66 
50 - 50 45 32 35 28 
60 - 60 30 30 20 20 
(See Appendix for meanings of abbrevi ations and units of measurement ) 
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TABLE 36 . Showing the results of s equential testing for Patient# 27 . 
TEST 
Phase 1 
Phase 2 
Phase 3 
H.R . T. 
A.C.G. 
A.C . G.C. 
K.C.C . T. 
P.T. 
F.D.P. 
G. E. F . 
Plats. 
C. R. 10 
C.R. 20 
C.R. 30 
C.R. 60 
M.R . I . 
M. R.A . T. 
L-_ __ - -- - -
'Pre' refers to preoperative tests and the numerals following 
the preoperative mean column indicate days following gastrectomy. 
Columns headed '%' show the percentage change from the pre-
operative mean. 
PRE PRE PRE X 1 % 3 % 5 g, 0 7 % 
- 480 480 387 19 357 26 428 11 443 8 
- 150 150 147 2 125 17 125 17 133 11 
- 36 36 35 3 33 8 32 11 32 11 
- 88 88 110 25 97 10 84 5 73 17 
- 58 58 58 0 57 2 60 3 65 12 
- 65 65 64 2 62 5 65 0 62 5 
- 50 50 68 44 38 41 
- 14 14 14 13 13 13 
- N N 10-20 10-20 N N 
:- 600 600 590 719 835 792 
- 600 600 609 1194 960 102 0 
- 31 31 49 27 20 21 
- 67 67 74 52 42 44 
- 77 77 80 64 57 58 
- 82 82 85 72 66 70 
- 15 15 10.5 19 25 24 
- 20 20 10 10 20 20 
---- -
(See Appendix for meanings of abbreviations and units of measurement) 
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TABLE 37. Showing the results of sequential testing for Patient # 28. 
TEST 
Phase 1 
Phase 2 
Phase 3 
H.R.T. 
A.C.G. 
A.C.G.~. 
K.C.C.T. 
P.T. 
F.D.P. 
G.E.F. 
Plats. 
C. R. 10 
C.R. 20 
C.R. 30 
C.R. 60 
M.R . I. 
M.R.A.T. 
'Pre' refers to preoperative tests and the numerals following 
the preoperative mean column indicate days following splenectomy. 
Columns headed '%' show the percentage change from the pre-
operative mean. 
PRE PRE PRE X 0 % 2 % 4 % 6 % 8 
477 570 523 450 14 385 26 365 30 430 18 432 
110 140 125 140 12 95 24 84 33 130 4 104 
34 34 34 36 6 33 3 23 32 25 26 24 
102. 102 102 94 8 50 51 63 38 76 25 74 
68 56 62 54 13 40 35 44 29 51 18 49 
- - - - - - - - - - - -
~@ 44 42 37 36 38 39 39 
12 12 12 13 12 11 12 13 
N N N N N N N N 
351 351 331 401 498 509 597 
260 260 201 289 356 473 537 
0 0 2 4 1 1 3 
2 2 5 37 31 15 19 
31 31 41 57 49 40 45 
65 65 69 65 57 61 63 
46 46 40 26 33 44 38 
60 60 30 20 20 30 30 
(See Appendix for meanings of abbreviations and units of measurement) 
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TABLE 38. Showing the r esults of sequential testing for Patient # 29. 
TEST 
Phase 1 
Phase 2 
Phase 3 
H.R.T . 
A. C.G. 
A.C . G. C. 
K. C. C.T. 
P.T. 
F.D.P. 
G. E.F. 
Plats. 
C. R. 10 
C. R. 20 
C. R. 30 
C. R. 60 
M.R.I. 
M. R.A.T. 
'Pre' refers to preoperative tests and the numerals following 
the preoperative mean column indicate days following gastrectomy. 
Columns headed '%' show the percentage change from the pre-
operative mean. 
PRE PRE PRE X 0 % 3 % 6 % 8 % 
508 500 504 450 11 394 22 335 34 430 15 
160 170 165 150 9 107 35 162 2 164 0 
44 37 40 36 . 10 35 13 32 20 35 13 
108 100 104 89 14 74 29 125 20 105 1 
50 50 50 46 8 35 30 40 20 39 22 
75 75 75 60 20 35 53 34 55 53 29 
45 45 45 41 39 41 43 
15 13 14 13 14 13 14 
N - N N N 10-20 N 
370 - 370 393 431 497 524 
391 - 391 376 398 437 506 
1 - 1 4 25 23 20 
4 - 4 23 48 56 51 
34 - 34 38 59 68 67 
64 - 64 56 65 75 70 
46 - 46 50 22 18 20 
30 - 30 20 10 20 20 
(See Appendix for meanings of abbreviations and units of measurement ) 
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Showing the general pattern of results 
of the phase 1 test in the group of 25 
patients who had major elective surgery. 
p.o.b. = pre-operative baseleine. 
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Showing the general pattern of results 
of the phase 2 test in the group of 25 
patients who had major elective surgery. 
p.o.b. = pre-operative baseline. 
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DISCUSSION 
Many laboratory tests, the results of wh£ch 
have been claimed to indicate a hypercoagulable state, 
have been predicated on the assumption that clotting 
tests in vitro show acceleration. 
If hypercoagulability in the postoperative 
patient is a manifestation of increases in either the 
concentration of circulating levels of certain procoagu-
lants, or their activity, then it would be expected 
that, in the postoperative patient, the rise in the 
levels and/or activity of these procoagulants, would 
result in accelerated clotting tests, where such factors 
are measured, providing that the assumption referred to 
in the first paragraphy is correct. 
It is widely accepted that the concentration of 
the known clotting factors in normal individuals is 
considerably in excess of that required for adequate 
haemostas£s. The further increase in the concentration 
of one or more procoagulants, following surg£cal opera-
tions, may not accelerate clotting tests which util£ze 
whole blood or pla,~ma s·amples. Shap;tro ·et al [1942), 
demonstrated a shortening of the prothromb~n t±me , 
lasting for a few days to three weeks, in patients with 
mycardial infarction using blood samples diluted with 
s·al;tne. Overman and Vright (1951) , using und£luted 
92. 
blood samples, failed to show a shortening of the 
prothrombin time. One may speculate that the reason 
for this paradox of results between the two tests could 
be related to the non-specific increase in circulating 
fibrinogen which follows after tissue trauma. The 
prothrombin time using diluted blood samples is sensi-
tive to further increases in fibrinogen concentration, 
whereas the test using undiluted blood is not, unless 
the fibrinogen concentration begins to fall. If ad-
sorbed plasma, containing fibrinogen, is used as the 
diluent instead of saline, no shortening of the pro-
thrombin time is observed (Tuft and Rosenfeld 1947). 
This study was performed without the knowledge 
of the work just referred to. However, the phase 1, 
phase 2, phase 3, heparin resistance, autocoagulography 
and autocoagulography control tests were designed to 
provide clotting test that may have increased sensitivity 
to rises in the levels of clotting factors or their ac-
tivity. In all of the tests just referred to, dilution 
of whole blood samples, processed in a standard way, 
forms the key element in each of the tests. 
Altho~gh the var~~tion in the concentr~tion of 
clotting fa,ctor~ i?: 'Ve:iY. wide ·;r.n g-rOUJ?:? o;E individuals 
of the same age ·and se:X. gx:oul?s, tne-r·e IS ev.1.:.dence that 
the ~ctivitY' o;E tne clotting factors in the same .indi-
dual is similar when tested sequentially. Thus 
Gormsen (1959), using a heparin resJ....stance test, 
tested his own blood, twice weekly, for 2 years and 
93. 
all results were between 11 and 13 minutes. Similarly, 
two other healthy persons were tested twice to four 
times a month for one year and gave results consistently 
between 12 and 14, and 13 and 16 minutes respectively. 
Many patients, suffering from cerebral or coronary 
thrombosis, similarly tested once a month, for periods up 
to four years, _ gave results consistently between 6 and 
7 minutes. Gormsen in describing these results, points 
out that although the values show marked dispersion, the 
same person exhibits extremely constant values under 
otherwise unchanged conditions. 
When a clotting test, obtained from a patient, 
is evaluated in terms of results obtained from a population 
of healthy persons, which are characterized by wide varia-
tions in clotting factor concentrations and/or activity, 
it is sometimes difficult to decide whether or not a change 
is significant. For example the normal range for factor 
VIII concentration is commonly given as being between 50% 
and 200%,. Thus, if the level of factor VIII in an indivi-
dual, followinc;J some arprol?;r-;ta te stimulus, ri_ses from 50% 
to 150%, the r:i:se in concentration still ;r-esults in a 
factor vrrr level well within norina,l lirrd'.ts. l'f however, 
the result be exa,mined in terms of· tfl.e pre-stimulus value 
of the ±.ndividual, then the post-stimulus result is likely 
abnormal for that individual, since the stimulus has pro-
94. 
duced a three~;eold j:ncre0;se tn the level of factor VIII. 
Dilutron of blood ~~ple~ prior to using the blood in 
various test systems, will undoubtedly increase the sensi-
tivity of the test, but will also increase the dispersion 
of results, result±ng in an even wider range of values in 
any population tecoted. For these reasons, this study 
has concentrated on following the haemostatic changes 
that result from surgery, using the patient ' s own pre-
operative values as a baseline. All postoperative reEults 
occurring in each individual patient have been compared 
to the pre-operative baseline. 
The results of the phase 1, phase 2, phase 3, 
autocoagulography, autocoagulography control and heparin 
resistance tests in the sequentially studied normal males 
and females (see TabJes 4 to 9, pages 45 to 50) . In 
all individuals forming this small group, with the excep-
of normal female # 2, the tests showed a small degree of 
variability during testing. The results of normal female 
#2 were, in all probability, influenced by the cessation 
of oral contraceptives. 
Tables 10 and 11, tpages 51 and 52), show the 
results of ltffiLted ~equential testtng of patients #1 and 
#2, who were ~cheduled for sur9er·y, tn;Eormed of this, but 
who did not ~ub~equeritly undergo ·~rgery. These results 
were incl-uded ±n order to ascertain whether or not the 
usual pre~operative apprehension, experienced by most 
95. 
patients, resulted tn sign:j..f:j..ca,nt changes in coagula-
bility. The results were remarkably consistent during 
the period of testing. 
Patients # 3 and #4, underwent minor surgical 
operations involving limited surgical dissection under 
general anaesthesia. These limited results (see 
Tables 12 and 13, pages 53 and 541, suggest that minor 
surgery under general anaesthesia does not result in 
significant changes in coagulability in the early post-
operative period. 
The results of the phase 1, phase 2 and heparin 
resistance tests iri the main group of 25 patients who had 
major elective surgery, all show increased coagulability, 
which is apparant very soon after the surgical operation. 
Similar results are seen in the data obtained from the 
autocoagulography and autocoagulography control tests. 
(see Figures 12-13, pages 81 and 82, and Figures 15-17, 
pages 84 - 86) • The similarity of the rise in coagula-
bility demonstrated by all of these tests, during the 
first few days following surgery, is not suprising, since 
it is likely that all of the separate tests measure some 
co:mmon clotting a.ctivity. The de;monstrat.ton of increased 
coagulability by a nl.l1Ilbe.r of dit'fe.rerit tests lends support 
to the COnCe}?t o;f a, developing h2,'!?ei?Coa,gP_lable state in 
the postsurgical patient, .if increased levels of clotting 
factors and/or a .ct.iv.ity satisfies one criterion for the 
Table 39. 
TEST 
Phase! 
Phase 2 
Heparin 
96. 
Showing the postoperative day on 
which a maximum increase in coagu-
lability was observed in each of the 
phase 1, phase 2, heparin resistance, 
autocoagulography and autocoagulography 
control tests for Patient # 5. 
(Cholecystectomy) • 
POSTOPERATIVE DAY ON 
WHICH PEAK COAGULABILITY 
WAS OBSERVED. 
Five 
Five 
Resistance Five 
Autocoagulography Three 
Autocoagulography 
Control Five 
Table 40. 
TEST 
Phase 1 
Phase 2 
97. 
Showing the postoperative day on 
which a maximum increase in coagu-
lability was observed in each of the 
phase 1, phase 2, heparin resistance, 
autocoagulography and autocoagulography 
control tests for Patient # 6. (Bowel 
Ressection) • 
POSTOPERATIVE DAY ON 
WHICH PEAK COAGULABILITY 
WAS OBSERVED 
Five 
Five 
Heparin Resistance Five 
Autocoagulography Three 
Autocoagulography 
Control · Five 
Table 41. 
TEST 
Phase 1 
Phase 2 
9 8. 
Showing the postoper~tive day on 
which max~mum increase in co~gu­
lability was observed in each of the 
phase 1, phase 2, heparin resistance, 
autocoagulography and autocoagulography 
control tests for Patient# 7. (Re-
moval of large pelvic tumour) • 
POSTOPERATXVE DAY ON 
WHICH PEAK COAGULABILITY 
WAS OBSERVED 
Four 
Four 
Heparin Resistance Four 
Autoco~gulography Four 
Autocoagulography 
Control Four 
Table 42. 
TEST 
Phase 1 
Phase 2 
99. 
Show~ng the ~ostoperat~ve day on 
which a max~mum increase in coagu-
lability was observed in ea,ch of the 
phase l, phase 2, heparin resistance, 
autocoagulography and autocoagulography 
control tests for Patient # 8. 
(Gastrectomy) • 
POSTOPERATLVE DAY ON 
WHICH PEAK COAGULABILITY 
WAS OBSERVED 
Three 
Three 
Heparin Resistance Six 
Autocoagulography Three 
Autocoagulography 
Control Three 
Table 43. 
TEST 
Phase 1 
Phase 2 
100. 
Showing the postoperative da.y on 
which a maxLmum increase in coagu-
lability was observed in each of the 
phase 1, phase 2, heparin resistance, 
autocoagulography and autocoagulography 
control test for Patient # 9. 
(Vagotomy and Pyloroplasty) • 
POSTOVERATIVE DAY ON 
WHICH PEAK COAGULABILITY 
WAS OBSERVED 
Eleven 
Ten 
ffepa.rin Resistance Eleven 
Autocoa.gulography Nine 
Autocoagulography 
' Control Eleven 
Table 44. 
TEST 
Phase 1 
Phase 2 
101. 
Showing the postoperative da.y on 
which a maximum i,ncrea~e in coagu-
lability was observed in each of the 
phase 1, phase 2, heparin resistance, 
autocoagulography and autocoagulography 
control tests for Patient # 10. 
(Thoracotomy) . 
POSTOPERATrVE DAY ON 
WHICH PEAK COAGULABILITY 
WAS OBSERVED. 
Ten 
Four 
Heparin Resistance Eight 
Autocoagulography Four 
Autocoagulography 
Control Four 
p 
Table 45. 
TEST 
Phase l 
Phase 2 
102. 
Showing the postoperative day on 
which. a JUaxinlUil\ increase in coagu-
lability was observed in each of the 
phase l, phase 2, hepari.n resistance, 
autocoagulography and autocoagulography 
control tests for Patient # ll. 
(Gastrectomy) . 
POSTOPERATIVE DAY ON 
WHICH PEAK COAGULABILITY 
WAS OBSERVED. 
Eight 
Eight 
Heparin Resistance One 
Autocoagulography Six 
Autocoagulography 
Control No increase demonstrated 
Table 46. 
TEST 
Phase 1 
Phase 2 
103. 
~hewing the po~topera.tiye da.y on 
which· a n1axiJnum i,ncrea.~e in coagu-
lability was observed i n each of the 
phase 1, ph~se 2, heparin resista.nce, 
autocoagulograph y and au tocoagulography 
control tests for Pa.tient # 12. 
(Right Nephrectomy) • 
POSTO;E?ERATIVE DA~ ON 
WHICH PEAK COAGULABILITY 
WAS OBSERVED. 
Eight 
Eight 
Heparin Resistance Eight 
Autocoagulography Four 
Autocoagulography 
. . 
Control Eight 
Table 47. 
TEST 
Phase l 
Phase 2 
104. 
~howi.ng the po~toperatiye day on 
whi.ch a maxLm~m increape in coagu-
lability was observed in each of the 
phase l, phase 2, heparin resistance, 
autocoagulography and autocoagulography 
control tests for ~atient # 13. 
(Cholecystectomy) • 
POSTOPERATIVE DAY ON 
WHICH PEAK COAGULABILITY 
WAS OBSERVED 
Four 
Four 
Heparin Resistance Four 
Autocoagulography Four 
Autocoagulography 
Control Four 
Table 48. 
TEST 
Phase l 
Phase 2 
Heparin 
lOS. 
Showing the po?toperatiye day on 
which a )IlaximU!Il increase in coagu-
lability wa.?' observed i n each of the -
phase 1, J_?hase 2, heJ_?ari.n resistance, 
autocoagulography and autocoagulography 
control tests for ~atierit # 14. · 
(Laparotomy with removal of intesti nal 
PolyJ_?s and Adhesions } . 
POSTOPERATI~VE DAY ON 
WHICH PEAK COAGULABILITY 
WAS OBSERVED. 
Five 
Si.x 
Resi.stance S i x 
Autocoagulography Five 
Autocoa.gulography 
Control F i ve 
jiiiP 
Table 49. 
TEST 
l?hase 1 
Phase 2 
106. 
$howi,ng the postoperative day o n 
whi,ch. a maxi.Jllull} i,ncrea~e i~n coagu -
labi lity was observed in each o;E the 
phase l, phase 2, heparin res.i stance, 
autocoagulography and autocoagulography 
control tests for Vatierit # 15. 
(Splenectomy) • 
POSTOPERAT:LVE DAY ON 
WHI'CH PEAK COAGULABI'LITY 
WAS OBSERVED 
One 
Three and Seven 
Heparin Resi,stance Three 
Autocoagulography One 
Autocoagulography 
Control Three. 
Table 50. 
TEST 
Phase 1 
Phase 2 
107. 
Sh9w~ng the po~toperat~ye day on 
whlch· a Jllaxi_!qurq i:ncrea~e in coagu-
labil .;l.,t~(' was obaeryed ~n each of the 
phase 1, phase 2, he~~rin resistance, 
autocoagulography and autocoagulography 
control . tests for Patient # 16. · 
(Cholecystectomy} • 
POSTOPERATTVE DAY ON 
WHICH PEAK COAGULABILITY 
WAS OBSERVED 
One 
Five 
Heparin Res i stance Three 
Autocoagulography One 
Autocoagulography 
Control Three 
Table 51. 
TEST 
Phase 1 
Phase. 2 
108. 
Sho~~n9 the ~Qsto~erat~ye day on 
whLch a ~ax~~~ increa~e in co~gu­
la,bi.,lit;; wa? ob~eryed i .n each of the . 
pha~e 1, phase 2, heparin re~i~tance, 
autoco~gulography and autocoagulography 
control tests for Pat~erit i 17. · 
(Sub-total Gastrectomy} . 
POSTOPERATIVE DAY ON 
WHICH PEAK COAGULABILITY 
WAS OBSERVED. 
Three 
Three 
Heparin Resistance Four 
Autocoagulography Three and Eight 
Autocoagulography 
Control Three 
Table 52. 
TEST 
Phase 1 
Phase 2 
Heparin 
109 . 
. ~hawing the pO$.toperatiye . day on 
which. a _rqaxinfu:ri} increas e in coagu-
lab i_li ty was obs.er~ved i n each of the -. 
phase 1, phase 2, he.p-arin resi.stance, 
autocoagulography and ·autocoagulography 
control te~ts for Patient i 18. 
(Vagotomy) . 
POSTO"J?E:RATIVE DAY ON 
WHICH PEAK COAGULABILITY 
WAS OBSERVED 
Ten 
Three, Five and Nine 
Resistance Five and Ten 
Autocoagulography Three and Nine 
Autocoagulograph y 
Control Ten 
Table 53. 
TEST 
Phase l 
Phase 2 
110. 
~hawing the pos.toper.at:kve qay on 
whi,ch.' a '%axi:n)u)l) increase in coagu-
lability was observed in each of the 
phase l, · phase 2, hepa-rin res'istance, 
autocoagulography and autocoagulography 
control tests for Patient # l9. · 
(Exploratory Laparotomy) . 
POSTOPER,ATJVE DAY ON 
WHICH PEAK COAGULABILITY 
WAS OBSERVED 
Eight 
Four 
Heparin Resistance One 
Autocoagulography Eight 
Autocoagulography 
Control Four 
Table 54. 
TEST 
Phase 1 
Phase 2 
111. 
Show.;i.,ng the J?O$ toper.a tj__ ye day on 
wh..:lch a ..Itla.xi.nJurq increase in coa<;Ju-
labtl.;i.,ty was obaeryed in each ·of the -
phaa-e 1, phase 2, her;:>arin re$ista,nce, 
autocoagulography and autocoagulography 
control tests for . Patient # 20. 
(Cholecystec"tomy) • 
POSTOPERA,TIVE DAY ON 
WHICH PEAK COAGULABILITY 
WAS OBSERVED. 
Four 
Four 
Heparin Resistance Four 
Autocoagulography Eight 
Autocoagulography 
Control Four 
Table 55. 
TEST 
Phase 1 
Phase 2 
Heparin 
112. 
$ho'«:in<;r the ;PO~tope:J::'.a,.t.L,ye da,y on 
wh!ch a ~axLmu~ ~ncrea~e in coa<;ru-
la,bi.lity wa~ ob~eryed in each o;f! the -
pha;se 1, pha;$e 2, he~a.rin res-istance, 
au tocoagul<:>graphy and ·a.u tocoagulography 
control tests for l?ati.erit i · 21. 
CR.emoval of Abdominal Tumour} • 
POSTOPERATrvE DAX ON 
WHICH P~K COAGULABILITY 
WAS OBSERVED 
Three 
Three 
Resistance Three 
Autocoagulography Three 
Autocoagulography 
. . Control Two 
Table 56. 
TEST 
Phase 1 
Phase 2 
113. 
Showing the postoperative day on 
which a ~qx~mum increase in coagu-
lability was ·observed in each o:( the 
phase 1, phase: 2, heparin resistance, 
autocoagu1ography and autocoagu1ography 
controi te~ts for Patierit # ~2. · 
(Spleriectomy) • 
POSTOPERAT~VE DAY ON 
WHICH PEAK COAGULABILITY 
WAS OBSERVED. 
Three 
Two 
Heparin :R,esistance Three 
Autocoagulography One and Seven 
Autocoagulography 
Control Three and Nine 
T~ble 57. 
TEST 
Phase l 
Phase 2 
114. 
$howing the po~tol?er-9.tive da,y on 
wh;i..,ch p, 1£\a.xi;m,wn tnc.;~;ea~e i,n co~gu­
la.bili,ty wa.~ ob~erved in e~ch ·a~ the -
phase 1, pha;se 2, hep:a.rin resistance, 
autocoagulogra.phy and autocoagulography 
control tests for Patierit t · ~3. 
(Exploratory Laparotomy) • 
POSTO~ERATXVE DAX ON 
WHICH ~EAK COAGULABILXTY 
WAS OBSERVED. 
Five 
FLve 
Heparin Resi~tance lrive 
Autocoagulography Three a.nd Five 
Autocoagulography 
Control Five 
Table 58. 
TEST 
Phase l 
Phase 2 
115. 
Showing the po~torer.ative day o n 
wh..;Lch a, ;maximurq increa~e i n coa.gu-
lab~lJ.,ty was ob~ery.ed in each of the . 
phase l, phase 2, heparin res~stance , 
autocoa,gulogr aphy and autocoagulography 
control tests for Patierit # 24. 
(Ruptured Apperidix) • 
~OSTQPERAT~VE DAY ON 
WHr CH PEAK COAGULABILITY 
WAS OBSERVED. 
Three 
Three 
Heparin ~esistance F~ve 
Autocoagulography Three 
. . 
Autocoagulog~a.phy 
Control Three 
Table 59. 
TEST 
Phase 1 
!:>hase 2 
ll6. 
Showi.~g the r;>os. topera,.t i::ve day on 
whlch a :Illax~u.m ;tnc.;r:ease ;tn coagu-
la.bi_li.ty wa,s ob~erved in each of the -
phase 1, f>hase 2, hep:a r i n res.istance, 
autocoagul9graphy and autocoagulograph y 
control te~ts for Patient i 25. 
(Laparotomy and Gastrectomy) • 
POSTO}?ERA,TJ:VE DAY ON 
WIUCH l?EAK COAGULABILTTY 
WAS OBSERVED. 
Seven 
Three 
Heparin Resi_stance Three 
Autocoagul~graphy Three 
Autocoagulography 
Control Three 
Ta,hle 60. 
TEST 
Phase 1 
Phase 2 
117. 
Show~n9 the po~toperat.Lve day on 
Whi.ch. a, Jlla,xj.Jl}UII! increa~e j_n C08,<JU-
lab .;i.,lity was obser~v.ed in each o;e the -
pha;~e 1, pha;se 2, heparin res.ista,nce, 
autocoagulography and autocoagulography 
control tests for Pati ent # 26. · 
(Spleriec.tomy} . 
POSTOPERATIVE DAY ON 
WHXCH PEAK COAGULABILITY 
WAS OBSERVED. 
One 
Three and Seven 
Heparin Resistance Three 
Autocoagulography One 
Autocoagulography 
Cont;r-ol Three 
Table 6·1. 
TEST 
J?hase l 
Phase 2 
ll8. 
$ho-w~~9 the pos toper~a, .ti..ye da,y on 
wh.;Lch a 1tl~i1tlu,m i.nc:;r;ease .in coa,gu-
la,bi,li ty was oh~erved in e:a;ch a:e the . 
phase l ·, phase ·2, hepar.i.n res·i :stance, 
autocoagulography and autocoagulography 
control tests for Patterit i 27, 
(Gastrectomy} • 
:POSTOPER.ATI:VE DAY ON 
WHLCR PEAK COAGULABILITY 
WAS OBSERVED. 
Three 
Three and :Five 
Heparin Resistance Seven 
Autocoagulography T~ee 
Autocoagulography 
Control Three and Seven 
TC\ble 62. 
TEST 
Phase 1 
Phase 2 
119. 
$how.;i.,n.<J the J?Osto.};_)er:a -t .j:.ye da,y on 
wh.Lch a 'll)~ilJ\Wlf .;i.,nc,;r;-ease ·t n coagu,... 
lability was oh~e;r:'yed in each o;e the --
pha:se 1, phase ·2, heparin r es·i :stance, 
autocoagulography and autocoagulography 
control tests for Patierit # 28. 
(Splenectomy) • 
POSTO~ERATrvE DAY ON 
WHICH PEAK COAGULABILITY 
WAS OBSERVED 
Four 
Four 
Heparin Resistance Two 
Autocoagulography Two 
Autocoagulography 
Control Two 
Table. 63. 
TEST 
J?hase 1 
Phase 2 
Heparin 
120. 
~howi!l-9 the I?ostQ}?era.t tye day on 
Wh.t.ch a, 1t1a,x$.Jt}UTI) j.,ncrease .~n CO~<;;JU­
lab.;[.lj:_ ty w~s ob~e.rve.d in e.a;ch ·af the--
pha;~e 1, phase ·2, hepa,;r-.j..n res.i:stS:nce, 
autocoagulogra.phy and autoco~gulography 
control tests ~or Patient i 29. 
(Gastrectomy}. 
POSTO:PERATX'VE DAY ON 
WHXCH PEAK COAGULABILITY 
WAS OBSERVED. 
Six 
Thr.ee 
Resistance Three 
Autocoagulography Three 
1:\utocoagulography 
. . . 
Control Six 
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def~nition of such a st~te. Lf, for all patients, 
the day on which the pe~k incre~se in coagulability is 
found, for each of the phase 1, phase 2, heparin resis-
tance, autocoagulography and autocoagulography control 
tests (see Tables 39 to 63, pages 96 to 120}. one may 
examine the time period in wh~ch increased coagulability 
reaches a peak for the group of 25 postsurgical patients. 
Figure 22 (page 122), illustrates the result of this pro-
cedure, ~nd it is readily apparant that the peak increase 
in coagulability occurs between days 3 to 5 postoperative, 
w~th an indication of a second smaller peak occurring 
around the 8th postoperative day (in some tests). A 
summary of the data presented in Figure 22, is shown in 
Figure 23 (page 123}. These figures are of interest 
s~nce the maximum incidence of pulmonary embolism has 
been claimed to occur on the seventh postoperative day 
(Evoy 1949). In addition Kakkar (1972), has shown that 
about 50% of venous thrombi in surgical patients form 
within the first 24 hours following surgery, and the re-
maining thrombi form within the third to seventh day 
after operation. Browse and Negus (1970), and Williams 
(1971) , present evidence that many patients who develope 
venous thrombosis will do so within the first three post-
operative days. These findings suggest that many venous 
thrombi are formed during the period, when, as shown by 
the phase 1, phase 2, heparin resistance,autocoagulography 
and autocoagulography control tests, increased blood 
coagulability can be demonstrated. 
122. 
10 I •• 
- -
•• 
I 9 •• • 
I I 8 >- .... - - ... • 
I I I I ~ ___. 
_j 7 • • • • 
m I I I <t 6 
_j • • • •• 
~ I I I I (!) 
~ 5 •• ···- .... • • I I I I I u 4 
·-- ·-· 
.... .. 
-
~ I I I I I <t 3 ··-· -:ua -·- -== •:n-w ·-· I I I I n_ 2 
-
• •• . ' 
LL I I I 0 1 
---
• .. ... 
~ 
0 I I I I 0 t t t t t 
0 
N r-: 0 (9 TEST ~ cr: u. 0. Q_ Q_ 
I <( <t 
F;i,<;J. 22. ?ho~j.~g the nuJl)ber of each of the f?hase 1, 
pha~e 2, heparin resistance, autocoagulo-
graphy and autocoagulography control tests 
· which demonstrated maximum increased coagu-
lability on different postoperative days 
for the group of 25 patients who had major 
elective surgery. 
F~g. 23. 
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shows the peak increases i_n coagulabi.lity 
found by obtaining the total number of 
all tests (phase · 1, phase 2, heparin re-
sistance, autocoagulography and autocoagu-
lography control . tests}, showing peak in-
creases in coagulability on various post-
operati.ve days. 
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The results of the phase 3 test show consider-
able dispersion and although many patients demonstrated 
an increased coagulability, again having a peak increase 
around days 3 to 5 postoperative, others showed a de-
crease in coagulability, which was sometimes very stri-
king (see Figure 14, page 83). These results however, 
are not to be unexpected, since the results of clotting 
tests which utilize tissue thromboplastin (e.g. the pro-
thrombin time), are variable in postoperative patients, 
some showing a shortening of the prothrombin time, that 
is, increased coagulability (Sandrock et al 1948), others 
show an increased prothrombin time (decreased coagulabi-
lity), as demonstrated by Egan et al (1974), and still 
others showing no change in coagulability (Kimche and 
Eisenkraft l97l) . 
Postsurgically, in most patients, an increase 
in coagulability was demonstrated with the heparin resis-
tance test as used in this study. The test has been 
used with many modifications to study patients in whom 
a hypercoagulable state is thought to exist. Ogura 
(1946) found accelerated heparin sensitized clotting 
tests in 21 of 27 patients with recent coronary throm-
bosis. Rosenthal (1952), found similar acceleration in 
14 o£ 19 cases of recent coronary thrombosis and Paller 
(1953), found acceleration in 37 of 50 cases of recent 
thromboembolic disease, findings supported by the observa-
125. 
tions of Peel (1953) . Gormsen (1959), found accelera-
ted heparin sensitized clotting times in 148 patients 
during the first 24 hours after acute cardiac infarction, 
in 95 cases of cerebral thrombosis, confirmed by arterio-
graphy and all cases of venous thrombosis. Such reports 
lend support to the concept that accelerated clotting tests, 
sensitized with heparin, may have value in the detection 
of a hypercoagulable state. 
In this study, the increased in vitro coagulabi-
lity, found in most patients during the first postoperative 
week, as demonstrated with the heparin resistance test, 
confirms the findings of Waugh and Ruddick (lg44), Silver-
man (1948), Holger-Madsen and Schiolar (1960), Gormsen and 
Haxholdt (1960), of a similar postoperative increase. 
Both of the standard clotting tests employed in 
this study, namely the kaolin-cephalin clotting time (kaolin 
activated partial thromboplastin time) and the one stage 
prothrombin time, were comparatively poor indicators of 
postsurgical increases in coagulability. Egan et al 
(1974), in a series of 39 postsurgical patients, found that 
48% of the patients had a shortened partial thromboplastin 
time immediately following surgery, 8% showed shortening 
on the first postsurgical day, 12% between the third and 
fourth, and 25% between the fifth and sixth days. Apart 
from those results which showed acceleration, most of the 
patients in this study had results which fell within the 
normal limits. 
It has been shown by Ygge (l970b) , that postsurgically 
there is a significant increase in the levels of factor 
VIII and fibrinogen. It is well known that decreases 
in the concentration of clotting factors, participating 
in the intrinsic pathway of coagulation (see Figure 24, 
page 127), results in prolongation of the kaolin-cepha-
lin clotting time (partial thromboplastin time) . Thus 
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a deficiency of factor VIII and/or fibrinogen, would be 
expected to lengthen the result , while increases in the 
levels of the same factors might be expected to shorten 
the result. In this study however, most of the kaolin-
cephalin clotting times remained within normal limits, 
althogh the majorlty of results lie beneath the mean of 
the normal range and the mean daily value for patient 
results has an oscillating characteristic (see Figure 19, 
page 88}. These results would suggest, that the test, 
wh±le being sensitive to deficiencies in one or more 
clotting factors, is not very sensitive to increases in 
clotting factors or their activity, and may be unsuitable, 
in an unmodified form for use in the study of the hyper-
coagulable state. 
Postsurgically, the alterations in the numbers 
of circulating platelets, namely an initial decrease, 
followed by a steady increase during the first postsurgi-
cal week, has confirmed the findings of Dawbarn et al 
(1928), Potts and Pearl (1941), Adams (1944), Ham and 
Slack {1967), Fogliano et al (1973) and Egan et al (1974). 
12 7. 
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Similarly, the change in fibrinogen levels, 
namely that of a steady and in most cases, an immediate 
increase, is a confirmation of the findings of Warren 
et al {1950), Atkins and Hawkins {1969), Ygge{l970a,b), 
Hammer et al {1973) and Egan et al {1974). 
The majority of patients, at some time during 
the first postsurgical week, were characterised by the 
presence of low levels of serum fibrin{ogen) degradation 
products. Of the group of 25 patients who had major 
elective surgery, 21 patients {84%) at some time during 
the first seven postsurgical days, had small increases 
in the concentration of fibrin{ogen) degradation products. 
Only 4 patients, {16%) gave completely negative assays. 
The results of these assays are seen in Table 64, page 
129) . It is of interest that, of the patients who 
produce the fibrin{ogen) degradation products, more patients 
had increased levels between days l and 4 postsurgically. 
These findings are in accord with the recently published 
work of Egan et al {1974), who found an increase in the 
levels of serum fibrin{ogen) degradation products in all 
of 39 postsurgical patients, with more positive findings 
being found on the third and fourth postsurgical days. 
The changes in clot retraction were studied with 
an original technique. It would be expected that the 
changes in clot retraction will be influenced largely by 
the following factors: l) the numbers of circulating 
Table 64. 
Post-op 
' Day 
l 
2 
3 
4 
5 
6 
7 
8 
9 
10 
129 . 
Showing the relati o n s h ip between serum 
fibrin(ogen l degradation products and 
the postope rative peri od in wh ich these 
products we re found i n the group of 25 
pat ients who had major elective surgery. 
Level of Fibri n(ogen) Degradation 
Products. 
l0-20ug/ml 20 - 40ug/ml 40-80u g/rnl 
# o f patients # of patients # of patients 
7 0 0 
3 0 0 
8 2 0 
4 l l 
l 0 0 
3 l 0 
0 0 0 
2 0 0 
0 0 0 
0 0 0 
platelets, 2) the functional activity of platelets, 
3) the concentration of fibrinogen and 4) the numbers 
of erythrocytes (and to a lesser extent, leucocytes) . 
In this study, no patient had a change in the packed 
+ cell volume of greater than - 9% during the first 
5 postsurgical days. It is therefore highly unlikely 
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that the changes in the numbers of circulating red cells 
would have any appreciable effect on the clot retraction 
studies. 
Budtz-Olsen (1951) in his admirable monograph, 
records the results of his experiments to determine the 
role of various factors in clot retraction. He demon-
strated that, with a constant number of platelets, clot 
retraction becomes progressively less with increasing 
concentrations of fibrinogen, and if the concentration 
of fibrinogen reaches very high levels, retraction may 
be inhibited. With a constant fibrinogen level, clot 
retraction becomes progressively less as the numbers of 
platelets decrease. It is therefore likely that the 
changes in clot retraction in this study, will reflect 
the quantitative and qualitative characteristics of the 
platelets interecting with the changing fibrinogen levels. 
Budtz-Olsen (1951), also points out that all other factors 
present in the plasma, play only a minute role in the 
phenomenon of clot retraction, a suggestion which is fully 
supported by his experimental observations. The blood 
samples used for the clot retraction studies were, as 
for most of the tests used in this study, diluted with 
tris buffer. Such dilution has been shown to have no 
effect on clot retraction (Arthus and Chaperio 1908, 
Masy Magro 1924, Lampert 1932, and MacFarlane 1938). 
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The results of the clot retraction studies in 
the group of 25 patients who had major elective surgery 
(see Tables 14 to 38, pages 56 to 80), indicate that 
on the first postsurgical day, when the greater majority 
of patients were characterized by a slight decrease in 
the platelet count (see Figure 20, page 89) accompanied 
by an insignificant change in the fibrinogen level (see 
Figure 21, page 90), an increase in clot retraction was 
found in 50% of the patients. If, as results indicate, 
the platelet count and the fibrinogen level show no real 
change, then it would seem logical to expect no change 
in the clot retraction activity. One may speculate that 
the increase in clot retraction may be related to the 
release, from the bone marrow, of young platelets with 
greater clot retractive ability. It is has been demon-
strated by Enticknap et al (1970), that the size of the 
platelet increases postsurgically and that the peak in-
crease in size occurs during the first to third postsur-
gical days. The peak increase in size occurred before 
the platelet count showed any significant increase. The 
change in size was also accompanied by changes in adhesi-
l32. 
vity and aggregability to adenosine diphosphate. Such 
evidence suggests that some changes in platelet morphology 
and physiology are to be expected in the early postsurgical 
period. Table 65 (p~ge l33), shows the results of the 
median retractive index for all patients in the group. If 
the mean median retractive index for the whole group is 
found for each day in the surgical period, and the data is 
graphically depicted (see Figure 25, page l34), a change 
in the index is seen to occur between the first and second 
postsurgical day. 
An examination of the maximum retractive activity 
time data for the group shows, that during the first three 
postsurgical days, 44% of the patients had a shortening 
of the maximum retractive activity time, 40% demonstrated 
no change from the preoperative value, and l6% showed an 
increase in this indice. When shortening of the indice 
occurs, this suggests that the available platelets are cap-
able of effecting retraction of the clot more rapidly, on 
the other hand, when the maximum retractive activity time 
increases, the ability of the available platelets to effect 
retraction, may in some way, be impaired. 
This rather limited data, suggests that in addition 
to changes in the platelet count, platelet adhesiveness and 
platelet aggregation, changes in the phenomenon of clot 
retraction may slo occur. It is tempting to speculate 
that, since the postsurgical patient is at high risk for 
the development of venous thromboembolism, changes in clot 
13~. 
TABLE 65. Showing the changes in the median retractive 
index~ in the m~in group of surgical patients. 
. . .. Days in. Surgical Period. 
Pat # Pre 0 l 1 2 I 3 I 4 I 5 -~ 6 1 7 I 8 I 9 lO 
Median Retractive .Index. 
5 58 33 45 43 55 
6 34 52 54 30 26 
7 32 24 25 27 36 
8 58 55 60 52 56 
9 - - 55 55 47 46 
lO - 60 40 35 43 37 
ll - 44 30 27 29 
12 - 43 47 60 47 
13 36 30 46 40 35 
14 26 27 30 24 29 27 27 
15 49 45 32 35 28 
16 56 49 46 44 52 
17 46 60 40 41 
18 54 59 57 52 50 45 52 
19 - 52 30 26 33 
20 32 36 32 28 43 
21 43 50 40 40 35 
22 43 47 47 35 28 
23 58 56 52 45 45 
24 50 53 43 55 
25 43 48 40 41 36 
26 50 45 32 35 28 
27 15 ll 19 25 24 
28 46 40 26 33 44 38 
29 46 50 22 18 20 
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retraction may influence the morphology and size of 
a recently established venous thrombus, and may also 
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be involved in the birth of an embolus. Clot retrac-
tion, by the extrusion of nascent thrombin from a freshly 
formed venous thrombus, may result in an extension of the 
thrombus. The process of extension, brought about by the 
extrusion of nascent thrombin and its coagulant effect on 
fibrinogen, may result in the entrapment of fresh platelets, 
eading to further retraction. Under the conditions pre-
sent in a vein, occluded or partially occluded by a thrombus, 
freshly extruded thrombin would not readily be rendered 
innocuous by dilution with the circulating blood, since im-
pairment to blood flow would be expected. This process 
of repeated retraction, and its influence on fibrinogen 
and circulating platelets could result in the formation of 
long slender thrombi, dangerously waving to and fro in the 
blood stream, the flow of which may be partially restored 
through clot retraction. It is tempting to speculate, 
but very difficult to prove, that the more active the pro-
cess of clot retraction, the more likely the thrombus would 
be to extend and the greater the danger of it being dis-
lodges to form a potentially dangerous embolus. 
The increase in the concentration of fibrinogen, 
the numbers of circulating platelets and in the level of 
serum fibrin(ogen) degradation products in the majority 
of the postsurgical patients indicates that such patients 
should not have their haemostatic mechanism evaluated in 
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terms of the usual normal values. It is obvious 
for example, that a fibrinogen level of 200 mg/lOOml. 
plasma, found in a patient tested on the fifth post-
operative day, would likely be abnormal for this patient, 
in spite of the fact that the value falls within the 
commonly cited normal range of 200 - 400 mg./lOOml. 
plasma. Similarly, a platelet count of 200,000/c.mm. 
of blood, found on the same postsurgical day, may very 
well be abnormal, again in spite of the fact, that as an 
isolated test result, it falls well within the usual 
normal range. It is particularly important that these 
postsurgical changes be kept in mind when attempting to 
make a diagnosis of disseminated intravascular coagulation 
in postsurgical patients. The laboratory diagnosis of 
such a state, rests in part on the demonstration of a 
fall in the fibrinogen concentration and in the numbers 
of circulating platelets, together with an increase in 
the concentration of serum fibrin(ogen) degradation pro-
ducts. It would seem more appropriate that, in order 
to detect varying degrees of haemostatic failure in the 
postsurgical patient, evaluation of postsurgical test re-
sults be made with pre-surgical values, keeping in mind 
the changes that result from surgical operations. 
SUMMARY AND CONCLUSIONS 
The detection of increased coagulability of the 
blood (hypercoagulability?) in the post-operative patient 
can be accomplished providing the following laboratory 
procedures are established; a) that whole blood samples, 
processed in a standard way, and subjected to dilution 
be tested, b) that the patient's blood be tested prior to 
surgery and sequentially during the post-operative period 
and further, that the post-operative results be compared 
to those obtained prior to the surgical procedure, thus 
dispensing with the usual practice of evaluation of 
post-surgical findings with those obtained from a "normal" 
population. 
This study has demonstrated a peak increase 
in blood coagulability in vitro occurring around post-
operative days 3 to 4, and an indication of a lesser 
increase occurring at the end of the first post-operative 
week. 
It has been shown that in approximately half of 
the patients undergoing major elective surgery accelerated 
clot retraction was found. Thus documenting an additional 
alteration in the physiology of the platelet induced by 
surgery. 
This study has confirmed the increase in 
fibrinogen, platelets, and serum fibrin(ogen) degradation 
products in the post-operative patient. 
13 7 
Finally, since the increase in fibrinogen 
concentration, platelet count, and the concentration of 
serum fibrin(ogen) degradation products seems to be a 
characteristic response of most post-surgical patients, 
it is recommended that such patients, in times of possible 
haemostatic failure, such as that which occurs in 
disseminated intravascular coagulation, should have their 
haemostatic mechanism evaluated in terms of a pre-
operative study, rather than an evaluation based on the 
so-called "normal values". Any post-surgical evaluation 
of haemostasis must be made bearing in mind the haemostatic 
changes that result from surgical operations. 
l38 
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APl?ENDIX 
Abbreviations and Units of Mesurement 
Abbreviation 
H.R.T. 
A.C.G. 
A.C.G.C. 
P.T. 
K.C.C.T. 
G.E.F. 
F.D.P. 
M.R.I. 
Plats. 
C.R. 
Used in All Tables. 
Meaning Units of Mesurement 
Phase 1 
Phase 2 
Phase 3 
Heparin Resistance 
Test 
Autocoagulography 
Test 
Autocoagulography 
Control Test 
Prothrombin Time 
Kaolin-cephalin 
Clotting Time 
Gravimetric Esti-
mation of fibrino-
gen. 
Serum Fibrin(ogen) 
Degradation Products 
Median Retractive 
Index 
Maximum Retractive 
Activity Time 
Platelet Count 
Clot Retraction 
Seconds. 
Seconds. 
Seconds. 
Seconds. 
Seconds. 
Seconds. 
Seconds. 
Seconds. 
mg./lOOml.Plasma. 
micro-grams/ml. 
Minutes. 
Minutes. 
jc.mm. Blood. 
Percent. 




